WO2003020985A1 - Detection of genetic sequences using a bipartite probe - Google Patents

Detection of genetic sequences using a bipartite probe Download PDF

Info

Publication number
WO2003020985A1
WO2003020985A1 PCT/US2002/027865 US0227865W WO03020985A1 WO 2003020985 A1 WO2003020985 A1 WO 2003020985A1 US 0227865 W US0227865 W US 0227865W WO 03020985 A1 WO03020985 A1 WO 03020985A1
Authority
WO
WIPO (PCT)
Prior art keywords
sequence
nucleic acid
probe
hybridizing
molecule
Prior art date
Application number
PCT/US2002/027865
Other languages
French (fr)
Other versions
WO2003020985B1 (en
Inventor
Timothy A. Hodge
Shawn O'malley
Original Assignee
Transnetyx, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transnetyx, Inc. filed Critical Transnetyx, Inc.
Publication of WO2003020985A1 publication Critical patent/WO2003020985A1/en
Publication of WO2003020985B1 publication Critical patent/WO2003020985B1/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N35/00Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
    • G01N35/00584Control arrangements for automatic analysers
    • G01N35/00722Communications; Identification
    • G01N35/00871Communications between instruments or with remote terminals
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813Hybridisation assays
    • C12Q1/6834Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813Hybridisation assays
    • C12Q1/6834Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00Sampling; Preparing specimens for investigation
    • G01N1/28Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/30Staining; Impregnating ; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis
    • G01N1/31Apparatus therefor
    • G01N1/312Apparatus therefor for samples mounted on planar substrates
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N35/00Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
    • G01N35/02Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor using a plurality of sample containers moved by a conveyor system past one or more treatment or analysis stations
    • G01N35/025Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor using a plurality of sample containers moved by a conveyor system past one or more treatment or analysis stations having a carousel or turntable for reaction cells or cuvettes
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B50/00ICT programming tools or database systems specially adapted for bioinformatics
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B50/00ICT programming tools or database systems specially adapted for bioinformatics
    • G16B50/30Data warehousing; Computing architectures
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H40/00ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
    • G16H40/60ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
    • G16H40/67ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00277Apparatus
    • B01J2219/00351Means for dispensing and evacuation of reagents
    • B01J2219/00387Applications using probes
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00277Apparatus
    • B01J2219/00497Features relating to the solid phase supports
    • B01J2219/00527Sheets
    • B01J2219/00533Sheets essentially rectangular
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583Features relative to the processes being carried out
    • B01J2219/00603Making arrays on substantially continuous surfaces
    • B01J2219/00659Two-dimensional arrays
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00718Type of compounds synthesised
    • B01J2219/0072Organic compounds
    • B01J2219/00722Nucleotides
    • CCHEMISTRY; METALLURGY
    • C40COMBINATORIAL TECHNOLOGY
    • C40BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00Libraries per se, e.g. arrays, mixtures
    • C40B40/04Libraries containing only organic compounds
    • C40B40/06Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C40COMBINATORIAL TECHNOLOGY
    • C40BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B60/00Apparatus specially adapted for use in combinatorial chemistry or with libraries
    • C40B60/14Apparatus specially adapted for use in combinatorial chemistry or with libraries for creating libraries
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00Chemistry: analytical and immunological testing
    • Y10S436/80Fluorescent dyes, e.g. rhodamine
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00Chemistry: analytical and immunological testing
    • Y10S436/805Optical property
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/14Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333Saccharide [e.g., DNA, etc.]

Definitions

  • This invention relates to a method of detection or quantitation of genetic sequences in a sample of DNA using a bipartite probe and more specifically using additional amplification molecules to enhance the detectable signal.
  • the probe will be directly modified to contain at least one fluorescent, radioactive or staining molecule per probe, such as cyanine dye, Alexa dye, horseradish peroxidase (HRP) or any other fluorescent signal generation reagent.
  • the fluorescent signal generation reagent includes, for example, Cyanine, Alexa, Texas Red, FITC, DTAF and FAM.
  • FAM is a fluorescein bioconjugate made of carboxyfluorescein succinimidyl ester (e.g. 5-FAM (Molecular Probes, Eugene, OR).
  • DTAF is a fluorescein dichlorotriazine bioconjugate.
  • the most important feature that differentiates this detection technology from PCR is that there is no physical reproduction of the genetic material of interest.
  • the new methodology detects the presence genetic material from the original source DNA.
  • the present invention is a process which indirectly detects or quantitates a target genetic sequence in any genetic sample using a bipartite probe.
  • a bipartite probe includes a probe genetic sequence capable of hybridizing with the target genetic sequence and an additional nucleic acid binding probe sequence beyond the probe genetic sequence. Bipartite probes are hybridized with both the target genetic sequence in the DNA sample and amplification probe molecules.
  • secondary signal generation molecules may also be added to the mixture to further increase signal. Additional, tertiary and quaternary etc. amplification molecules may successively be added to yield increase signal.
  • This invention provides a method for detection or quantitation of a target genetic sequence in a genetic sample an assay which involves using a bipartite probe and at least one detectable amplification molecule.
  • a bipartite probe has a nucleic acid binding sequence capable of hybridizing the target genetic sequence in a sample of DNA and a binding probe sequence capable of hybridizing with a nucleic acid sequence of a detectable amplification molecule.
  • An amplification molecule has a nucleic acid sequence capable of hybridizing the binding probe sequence of the bipartite probe. The amplification probe is detectable by a variety of methods.
  • this invention provides a method for detection or quantitation of a target genetic sequence in a genetic sample with an assay which involves using: a bipartite probe having a target nucleic acid binding sequence capable of hybridizing the target genetic sequence and an nucleic acid binding probe sequence capable of hybridizing with a nucleic acid sequence of a primary detectable amplification molecule and a primary detectable amplification molecule having a nucleic acid sequence capable of hybridizing the binding probe sequence of the bipartite probe.
  • this invention provides a method to increase signal strength in an assay for a target genetic sequence in a genetic sample involving the steps of: hybridizing at least one detectable amplification molecule with a bipartite probe in a hybridization solution, the bipartite probe having a target nucleic acid binding sequence capable of hybridizing the target genetic sequence and a binding probe sequence capable of hybridizing with a nucleic acid sequence of at least one detectable amplification molecule.
  • this invention provides a method to increase signal strength in an assay for a target genetic sequence in a genetic sample involving the steps of: hybridizing primary and secondary amplification molecules in a hybridization solution and adding a bipartite probe.”
  • the bipartite probe having a target nucleic acid binding sequence capable of hybridizing the target genetic sequence and a binding probe sequence capable of hybridizing with a nucleic acid sequence of at least one detectable amplification molecule.
  • this invention provides a method of forensic analysis for a target nucleic acid sequence involving the steps of: isolating human genomic DNA; immobilizing the human genomic DNA on a flat substrate; hybridizing the human genomic DNA with a bipartite probe having a target nucleic acid binding sequence capable of hybridizing the target genetic sequence and a binding probe sequence capable of hybridizing with a nucleic acid sequence of a primary detectable amplification molecule; and a primary detectable amplification molecule having a nucleic acid sequence capable of hybridizing the binding probe sequence of the bipartite probe; detecting the detectable amplification molecule; and correlating the detectable amplification molecule with the target nucleic acid sequence.
  • FIG. 1 is an illustration of the present method.
  • FIG. 2 is a graph showing percent formamide vs negative change in temperature.
  • the present invention provides a method for discriminating a genetic sequence using a bipartite probe to localize an amplification molecule.
  • dendrimer synthetic 3-dimensional polymer macromolecule that is prepared from simple branched monomer units.
  • the functionality of the macromolecule can be controlled and varied.
  • DNA deoxyribonucleic acid
  • DNA is a double-stranded molecule held together by weak bonds between base pairs of nucleotides.
  • the four nucleotides in DNA contain the bases: adenine (A), guanine (G) cytosine (C), and thyrnine (T).
  • A adenine
  • G guanine
  • C cytosine
  • T thyrnine
  • genome all the genetic material in the chromosomes of a particular organism; its size is generally given as its total number of base pairs.
  • genomic DNA all of the genetic information encoded in a cell. Lehninger, A.L., Nelson, D.L. Cox, M.M. (1993) Principles of Biochemistry, 2 nd ed., Worth Publishers, New York, NY.
  • microarray imager - is a reader used to detect samples bound or affixed to a flat substrate.
  • microarray technology ⁇ is a hybridization-based process that allows simultaneous quantitation of many nucleic acid species, has been described (M. Schena, D. Shalon, R. W. Davis, and P.O. Brown, "Quantitative Monitoring Of Gene Expression Patterns With
  • recombinant DNA A combination of DNA molecules of different origin that are joined using recombinant DNA technologies.
  • substrate Any three dimensional material to which sample or probe may be deposited that may have reactive groups to aid in attachment.
  • target genetic sequence includes a transgenic insert, a selectable marker, recombinant site or any gene or gene segment.
  • the present invention is a process which indirectly detects or quantitates a target genetic sequence in any genetic sample 10.
  • the genetic sample 10 can include genomic DNA, PCR amplicons, total RNA, mRNA, mitochondrial DNA, cDNA, plamid DNA, cosmid DNA and chloroplastic DNA.
  • a bipartite probe 1 includes a target nucleic acid binding sequence 2 capable of hybridizing with the target genetic sequence 3 and an additional nucleic acid binding probe sequence 4 adjacent to the target nucleic acid binding sequence 2.
  • a bipartite probe 1 is hybridized with both the genetic sample 10 including the target genetic sequence 3 and a detectable amplification molecule 6.
  • the detectable amplification molecule 6 includes a capture probe sequence 5 that is a nucleic acid sequence capable of hybridizing with the nucleic acid binding probe sequence 4 of the bipartite probe 1.
  • An amplification in molecule is any element which has the capacity to be detected while bound to a target.
  • a nucleic acid sequence attached to an amplification molecule can be referred to as a capture arm.
  • the capture probe sequence 5 is an example of a capture arm.
  • a capture arm is preferably about 31 bases in length, but can range from about 16 to 90 bases in length.
  • a capture arm to be capable of hybridization should be substantially linear in confirmation.
  • the 1 primary detectable amplification molecule 6 can be a dendrimer that includes a label in its core or more commonly the label is on the dendrimer arms.
  • the primary detectable amplification molecule 6 can also be a less branched or linear labeled or unlabeled oligonucleotides that can generate signal and/ or facilitate the attachment of other labeled molecules.
  • intermediary oligonucleotides may be hybridized to either the capture probe sequence or the binding probe sequence. Subsequently, this intermediary would bind to its remaining target. These intermediary oligonucleotides would not change the basic and novel aspects of the claimed method.
  • a secondary signal generation molecule may also be added to the hybridization mixture to further increase detectable signal.
  • tertiary 20 and quaternary 30 etc. amplification molecules may successively be added to yield increase signal.
  • a plurality of nucleic acid binding sequences 7 and 13 can be attached to the primary amplification probe molecule 6. These nucleic acid binding sequence must have a specific affinity for the capture arm of another amplification probe molecule. The number of bases that compose the nucleic acid binding sequence can vary based on the size of the genome under study.
  • the probe binding sequence 7 is capable of hybridizing with a single stranded genetic sequence 8 that includes a signal generating means 9. The single stranded genetic sequence 8 is hybridized to one of the capture arms of the primary detectable amplification molecule 6. This signal generating means 9 can include various labels.
  • the label can be enzymes, radioactive isotopes, flurogenic, chemiluminescent or electrochemical materials, or members of a specific binding pair such as biotin-avidin, biotin-streptavidin, folic acid-folate binding proteins.
  • covalent binding pairs include sulfhydryl reactive groups such as maleimides and haloacetyl derivatives and amine reactive groups such as isothio cynontes, succinimidyl esters, sulfonyl halides, and coupler esters, sulfonyl halides, and coupler dyes such as 3-methyl-2-benzothiazolinone hydrazone (MBTH) and 3-(dimethyl- amino) benzoic acid.
  • the nucleic acid binding sequence 13 is one of the capture arms of the primary amplification probe molecule 6.
  • a secondary detectable amplification molecule 8 and 11 can be used to further amplify the signal.
  • the secondary amplification molecule 11 can be a secondary signal generating dendrimer with nucleic acid binding sequences 12 and 14.
  • the nucleic acid binding sequences 12 and 14 are the capture arms of the secondary detectable amplification molecule 11. More specifically, the nucleic acid binding sequence 13 is capable of hybridizing with a nucleic acid binding sequence 12 attached to the secondary detectable amplification molecule 11.
  • the nucleic acid binding sequence 12 can be referred to as the capture arm of the secondary detectable amplification molecule 11.
  • a tertiary detectable amplification molecule 20 such as a tertiary signal generating dendrimer can be subsequently added to the hybridization solution.
  • the tertiary amplification molecule 20 includes a nucleic acid binding sequence 24 that is capable of hybridizing with a nucleic acid binding sequence 14 attached to the secondary detectable amplification molecule 11.
  • the nucleic acid binding sequences 24 and 26 of the tertiary amplification molecule 20 are the capture arms of the tertiary detectable amplification molecule 20.
  • the tertiary detectable amplification molecule 20 also includes a nucleic acid sequence 22 that is capable of hybridizing with a nucleic acid sequence 32 attached to a quaternary detectable amplification molecule, such as a quaternary detectable amplification molecule 30.
  • the quaternary detectable amplification molecule has a nucleic acid sequence 34 that is capable of binding an additional amplification molecule.
  • the nucleic acid binding sequences 34 and 32 of the quaternary detectable amplification molecule 30 are the capture arms of the quaternary detectable amplification molecule 30. Additional signal generating molecules can be added until the amount of quantitated signal exceeds the maximum values the detection instrument can record.
  • nucleic acid binding probe sequence 4 of the bipartite probe 1 may have reverse compliment sequence as the 5' end of reverse transcriptase.
  • the bipartite probe 1 would contain the binding sequence of:
  • This nucleic acid binding probe sequence 4 of the bipartite probe 1 is complimentary to the nucleic acid sequence 5 for an amplification dendrimer probe from Genisphere
  • a fluorescent dye is attached to the dendrimer core and/or the dendrimer arms. This fluorescent dye is a detectable label.
  • the target nucleic acid binding sequence 2 is specific for the target genetic sequence 3 of the genetic sample 10 respectively.
  • the binding probe sequence 4 of the bipartite probe 1 is free and does not bind to the target genetic sequence 3. Examples of bipartite probes 1, complementary to single copy genes, are shown the table below:
  • bipartite probes 1 complementary to Mouse Major Urinary Protein are shown in the table 2 below. These bipartite probes 1 are made one of the MUP genetic sequences, the target nucleic acid binding sequence 2 and a nucleic acid binding probe sequence 4, that is complementary to the nucleic acid sequence of an amplification molecule, which in this example is a dendrite probe.
  • An amplification molecule such as a dendrimer or tyramide, is introduced.
  • the amplification molecule is bound directly or indirectly to the bipartite.
  • the amplification molecules such as a dendrite probes, has a nucleic acid capture probe sequence 5 that is complementary to the nucleic acid binding probe sequence 4 of the bipartite probe.
  • the bipartite probe 1 complexed with nucleic acid capture probe sequence 5 of the amplification molecule may be hybridized to a secondary signal generating molecule, such as an additional dendrimers with complimentary sequences or a secondary labeled oligonucleotide such as nucleic acid sequence 8.
  • Free bipartite probes and excess amplification molecules are removed via several successive wash steps.
  • the bound detectable amplification molecule emits a detectable signal that can have a linear relationship to the number of bound molecules.
  • binding probe sequence 4 of the bipartite probe 1 and/or the capture probe sequences of any of dendrites capture probe sequences include, but not limited to biotinylation.
  • a detectable amplification molecule may have a signal molecule directly attached to it or it may activate or facilitate the attachment of another signal unit.
  • An example of a secondary signal generation element includes but not limited to enzymes and labeled antibodies. Multiple signals units may be used to amplify the signal of the target.
  • the bipartite probe 1, which is composed of the target nucleic acid binding sequence 2 and the binding probe sequence 4, is added to a genetic sample 10, preferably genomic DNA.
  • the target nucleic acid binding sequence 2 of the bipartite probe 1 specifically hybridizes to the target genetic sequence 3 of the genomic DNA sample 10.
  • the nucleic acid binding sequence 5 of the amplification probe molecule 6 specifically hybridizes to the binding probe sequence 4 elements of the bipartite probe 1.
  • the primary detectable amplification molecule 6 is a dendrimer and includes a fluorescent tag that functions as a label in an assay. The signal may further be increased by subsequently adding various forms of secondary, tertiary, quaternary etc signal generating units.
  • the amplification molecules are hybridized together prior to adding the bipartite probe 1.
  • the modification such as proteins (eg. Biotinylation), may be added to either the binding probe sequence of the bipartite and/or the capture probe sequence of the dendrite. This modification will allow for protein interaction resulting in indirect labeling.
  • DNA from a genetic sample is immobilized onto a substrate, preferably a glass slide.
  • the substrates typically have a reactive group attached to the surface to facilitate the immobilization.
  • Aldehyde reactive groups covalently coupled to the glass subsequently covalently immobilize the DNA via a dehydration reaction.
  • a Sodium Borohydrate Hydrate solution is added to reduce the unused aldehyde reactive groups to alcohol.
  • the bound DNA is denatured via heating the substrate above 94° C for five minutes. This heating process disrupts the hydrogen bonds between adenine, cytosine, guanine and thymine.
  • a bipartite probe 1 is added to the substrate suspended in a hybridization buffer and covered with a coverslip.
  • the bipartite probe 1 in solution is incubated at 43-55° C for one hour. During this incubation the target nucleic acid genetic sequence 2 of the bipartite probe 1 specifically hybridizes to the target genetic sequence of the sample DNA 10.
  • a three minute wash in 2X Saline Sodium Citrate (SSC) and a one minute wash in 0.2 X SSC removes any unbound bipartite.
  • Amplification molecules are suspended in a hybridization buffer and added to the substrate and coverslipped. The amplification molecules in solution are incubated at 50 - 55° C for one hour. During this incubation the binding probe sequence of the bipartite probe 1 specifically hybridizes to the capture arm of the amplification probe molecule.
  • the secondary signal generating dendrite probe has a nucleic acid capture probe sequence that is complementary to the capture probe sequence of the primary detectable amplification probe 6.
  • the secondary signal generating dendrite probes are suspended in a hybridization buffer.
  • the "secondary signal generating dendrite" probe in solution are incubated at 50-55°C for one hour. During this incubation the capture arm sequence of the secondary signal generating dendrite probe specifically hybridizes to the capture arm of the amplification probe molecule.
  • a secondary signal generating dendrite probe serving as a secondary amplification molecule are suspended in a hybridization buffer.
  • the secondary signal generating dendrite probe has a nucleic acid binding sequence that is complementary to the nucleic acid binding sequence of the primary detectable amplification molecule 6.
  • the bipartite probe 1 is complexed with capture probe sequences of the primary amplification molecule which may be complexed to a secondary amplification molecule.
  • the first consideration is to make sure the sequence is specific for the genetic target in the genome under study.
  • the four bases raised to the number of bases in the sequence (eg. 4 ⁇ umber of ases ) should be a number larger than the number of bases in the genome being studied.
  • the number of bases in the mouse genome is 3.0 x 10 9 .
  • the. calculation would be 4 16 which is 4.29 x 10 9 .
  • a target nucleic acid binding sequence of 15 bases would yield 4 15 which is 1.07 x
  • the optimal hybridization temperature is dependent on the length and composition of the oligonucleotide.
  • the melting temperature of each element determines the optimal hybridization of both the target nucleic acid binding sequence and the nucleic acid binding probe sequence of the bipartite probe. Each melting temperature is determined independently.
  • the melting temperature of a 20mer target nucleic acid binding sequence is 68.3°C.
  • a 20mer is long enough to confer specificity to the eukaryotic genome of 3.0xl0 9 base pairs.
  • the optimal hybridization temperature is 20-25°C lower than 68.3°C resulting in a 43.0°C hybridization temperature with a tradition buffer such as (1) 0.25
  • the same 20mer target nucleic acid binding sequence with the 68.3°C melting temperature in a 40% formamide buffer has a remarkably different optimal hybridization temperature.
  • the lower temperature of 20-25°C and additional decrease of 20°C is required resulting in an optimal hybridization temperature of 23.0°C.
  • the nucleic acid binding probe sequence 4 of the bipartite probe 1 is also determined in the same fashion.
  • the nucleic acid binding probe sequence 4 for a 3 lmer has a melting temperature of 94.0°C.
  • the melting temperate results in an optimal temperature of 70.0°C. i a 40% formamide solution the optimal hybridization temperature decreases 20°C resulting in a hybridization temperature of 50.0°C.
  • a 16mer target nucleic acid binding probe sequence 4 is' the minimum number of bases to confer specificity to the eukarotic genome.
  • a 16mer has a melting temperature of 54.0°C.
  • Traditional, hybridization buffers optimally hybridizing at 20°C less than the melting temperature yields optimal results at 29.0°C.
  • a 40% formamide buffer requires an additional 20°C decrease in temperature to optimal hybridize at 9.0°C.
  • the nucleic acid binding probe sequence 4 for a 3 lmer has a melting temperature of 94.0°C. 20-25°C below the melting temperate is the traditional range for optimal hybridization.
  • a traditional hybridization buffer has an optimal hybridization temperature of 70.0°C.
  • the optimal hybridization temperature decreases 20°C resulting in a hybridization temperature of 50.0°C-
  • the number of bases to confer specificity to a prokaryote with a genome of eighteen thousand base pairs is less than the number of bases to be discriminatory for the eukaryotic genome.
  • a 8mer has enough bases to be discriminatory for a genome of eighteen thousand base pairs.
  • An 8mer target nucleic acid binding sequence 2 will have a low melting temperature due to few number of bases.
  • An 8mer with a melting temperature of 27.0°C in a traditional buffer has a realized optimal hybridization at 2.0°C. Because of the 20°C drop in temperature below that of a traditional buffer, a formamide hybridization of an 8mer is not possible in formamide.
  • a 13mer target nucleic acid binding sequence 2 is long enough to confer specificity to a prokaryotic genome of eighteen thousand base pairs.
  • a 13mer with a melting temperature of 45.0°C will optimally hybridize in a traditional buffer at 19.0°C. Whereas it is possible to optimally hybridize in 40% formamide at 0°C.
  • the preferred number of bases for the target nucleic acid binding sequence 2 is 16-20 bases for the eukarotic genome. Whereas by contrast the preferred length of the target nucleic acid binding sequence 2 is 8-13 bases for prokaryotes with a genome of 18,000 base pairs. The preferred number of bases for the nucleic acid binding probe sequence 4 is for eukaryotes and prokaryotes is the same. A preferred length of 31 bases confers specifically to its compliment.
  • a sequence search known as a blast from public internet sites such as National Center for Biotechnology Information (NCIB) available at http://www.ncbi.nlm.nih.gov/ or private databases such as Celera's (Rockville, MD) should be performed.
  • NCIB National Center for Biotechnology Information
  • a blast of all known sequences for a particular species helps ensure specificity. If a blast reveals that a particular sequence exists in the genome then no preference will be appreciable between the target sequence and the endogenous sequence.
  • the secondary structures include stem loop structures and homodimers.
  • Stem loop structures form because of the affinity of one region of the bipartite for another region of the same bipartite, specifically between the guanine and cytosine residues. Whereas homodimer show an affinity for anther molecule of the same species. hi order to provide a capture arm capable of hybridization both of these 'secondary structures should be eliminated in a variety of ways. Simply selecting an alternative sequence that is not rich in guanine and cytosine often is all that is needed to produce a species with no stable secondary structures.
  • the sequence is sufficiently long enough, it is possible to delete the portion of the arm that participates in the formation of the secondary structure as long as the remaining element is sufficient for specific hybridization.
  • the application of heat sufficient to overcome the secondary structures is highly effective.
  • the temperature to optimally hybridize should be higher than the temperature to reduce secondary structures.
  • Secondary structures may also be reduced by the substitution of bases. Inosine is a nucleoside that can be substituted for a base participating in the formation of a secondary structure thereby destabilizing the structure.
  • substituting a base that forms a mismatch will also destabilize the secondary structures. Although, there must be sufficient base pairing between the capture arms and the target to yield adequate hybridization in spite of the mismatch.
  • the 29 th base which is guanine
  • adenine was substituted with adenine in order to disrupt the stem loop structure in a secondary signal generating dendrimer.
  • This base mismatch destabilized the stem loop structure, which then allows nucleic acid arm to participate in a hybridization reaction.
  • the melting temperature to disassociate the hairpin structure because of the base mismatch was 7°C as opposed to 70°C for the perfect match.
  • the mismatch does not prevent hybridization between amplification molecule and the secondary signal generating dendrimer.
  • the secondary signal generating dendrimer had a capture sequence of: 5' - GGC CGA CTC ACT GCG CGT CTT CTG TCC CAC C -3' (SEQ ID NO: 14) which had the following characteristics: TABLE 3
  • the sequence 5' GGC CGA CTC ACT GCG CGT CTT CTG TCC CGC C 3' (SEQ ID NO: 19) is the perfect match for the capture probe sequence of the amplification molecule however it has the following characteristics:
  • HOMODIMER 5' GGCCGACTCACTGCGCGTCTTCTGTCCCGCC 3' (SEQ ID NO:22)
  • Formamide changes the melting temperature and expected optimal hybridization temperate One degree Celsius for every 2% formamide added beyond the traditionally accepted optimal hybridization range of 20-25° C below the melting temperature. Therefore adjusting the percentage can dramatically affect the thermal requirements for a successful reaction.
  • the Binding Probe Sequence of the bipartite which is: 5' - GGC CGA CTC ACT GCG CGT CTT CTG TCC CGC C -3' (SEQ ID NO:24) with the following characteristics:
  • Synthetic single stranded DNA oligonucleotides 51mers bipartites were synthesized by hivitrogen (Carlsbad, CA). The dry bipartites were rehydrated with deionized water at a concentration of 200 ⁇ M. The bipartites mixture consisting of l ⁇ l of bipartite, 4.5 ⁇ l of 20xSSC (Saline Sodium Citrate) and 24.5 ⁇ l of deionized water was added to the wells of a Whatman (Clifton, NJ) polypropylene 384, 80 ⁇ l V-bottom wellplate.
  • the bipartites were printed with a SpotBot (Telechem, Sunnyvale, CA) onto Superaldehyde substrates (Telechem, Sunnyvale, CA) in a grid pattern of five columns by six rows.
  • the printed substrate is . loaded into a heating cassette.
  • the heating cassette is composed o a beveled top plate, prefabricated spacers, a metal frame and tension clips.
  • the substrate is lowered into the metal frame and spacers are placed on top of the substrate running lengthwise along the edge.
  • the beveled top plate is then lowered on top of the substrate only separated by the spacers.
  • the metal tension clips are then applied to the heating cassette, which holds the cassette together securely.
  • the heating cassette is placed on the exterior platform of the heating block.
  • the heating block's exterior surface is thermally controlled by different temperature fluids being perfused by external circulator baths.
  • the contact between the heating cassette substrate and the heating block permits a highly efficient thermal transfer.
  • the slide was then washed six times with 350 ⁇ l of deionized water.
  • the remaining reactive aldehyde groups were removed from the slide by washing the slide six times with 350 ⁇ l of Sodium Borohydrate (0.4 gNaBFLi, lOmls 100% ethanol, 30mls of PBS) followed by six washes with 350 ⁇ l of deionized water.
  • 4 ⁇ l of CY3 dendrimer (primaiy detectable amplification Molecule) and 116 ⁇ l of 40 % Formamide, 4XSSC, 1% SDS, 2X Denhardt's Solution was incubated at 50°C for 60 minutes.
  • the substrate was washed seven times with 350 ⁇ l of 2X SSC, 0.2% SDS, followed by eleven 350 ⁇ l washes in 2X SSC and two 350 ⁇ l washes in a 0.2X SSC.
  • the slides was dried and scanned at a gain of 255, 200 and 100.
  • the following results from 60 samples demonstrate a single amplification molecule attached to a bipartite and can be used as a baseline for additional amplifications.
  • Synthetic single stranded DNA oligonucleotides 51mers bipartites were synthesized by Invitrogen (Carlsbad, CA). The dry bipartites were rehydrated with deionized water at a concentration of 200 ⁇ M. The bipaitites mixture consisting of l ⁇ l of bipartite, 4.5 ⁇ l of 20xSSC (Saline Sodium Citrate) and 24.5 ⁇ l of deionized water was added to, the wells of a Whatman (Clifton, NJ) polypropylene 384, 80 ⁇ l V-bottom wellplate.
  • the bipartites were printed with a SpotBot (Telechem, Sunnyvale, CA) onto Superaldehyde substrates (Telechem, Sunnyvale, CA) in a grid pattern of five columns by six rows;
  • the printed substrate is loaded into a heating cassette.
  • the heating cassette is composed of a beveled top plate, prefabricated spacers, a metal frame and tension clips.
  • the substrate is lowered into the metal frame and spacers are placed on top of the substrate running lengthwise along the edge.
  • the beveled top plate is then lowered on top of the substrate only separated by the spacers.
  • the metal tension clips are then applied to the heating cassette, which holds the cassette together securely.
  • the heating cassette is placed on the exterior platform of the heating block.
  • the heating block's exterior surface is thermally controlled by different temperature fluids being perfused by external circulator baths.
  • the contact between the heating cassette substrate and the heating block permits a highly efficient thermal transfer.
  • the slide was then washed six times with 350 ⁇ l of deionized water.
  • the remaining reactive aldehyde groups were removed from the slide by washing the slide six times with 350 ⁇ l of Sodium Borohydrate (0.4 g
  • CY3 secondary signal generating dendrimer 1.5 ⁇ l of CY3 secondary signal generating dendrimer with the capture sequence of 5'-GGC CGA CTC ACT GCG CGT CTT CTG TCC CAC C -3' (SEQ ID NO:29) and 114 ⁇ l of 40 % Formamide, 4XSSC, 1% SDS, 2X Denhardt's Solution, was incubated at 55°C for 60 minutes.
  • the substrate was washed seven times with 350 ⁇ l of 2X SSC, 0.2% SDS, followed by eleven 350 ⁇ l washes in 2X SSC and two 350 ⁇ l washes in a 0.2X SSC to remove any excess dendrimer.
  • the slides was dried and scanned at a gain of 255, 200 and 100.
  • results from 60 samples demonstrate an amplification of signal from a secondary signal generating dendrimers hybridized to an amplification probe molecule which in turn is hybridized to a bipartite.
  • the secondary signal enhancement represented indicates a three to seven fold increase in signal over the baseline single bipartite and amplification probe molecule hybridization.
  • 200ng/ ⁇ l of human genomic DNA was isolated using Sambrook, J., Fritsch, E.F., and Maniatis, T., in Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press, NY, Vol. 1, 2, 3 (1989).
  • 20xSSC Saline Sodium Citrate
  • 24.5 ⁇ l of human genomic DNA was added to the wells of a Whatman (Clifton, NJ) polypropylene 384, 80 ⁇ l V-bottom wellplate and mixed.
  • the genomic DNA was printed with a SpotBot (Telechem, Sunnyvale, CA) onto Superaldehyde substrates (Telechem, Sunnyvale, CA) in a grid pattern of five columns by six rows. The printed substrate were dried and loaded into a heating cassette.
  • the heating cassette is composed of a beveled top plate, prefabricated spacers, a metal frame and tension clips.
  • the substrate was lowered into the metal frame and spacers were placed on top of the substrate running lengthwise along the edge.
  • the beveled top plate was then lowered on top of the substrate only separated by the spacers.
  • the metal tension clips were then applied to the heating cassette, which held the cassette together securely.
  • the heating cassette was placed on the exterior platform of the heating block.
  • the heating block's exterior surface is thermally controlled by different temperature fluids being perfused by external circulator baths.
  • the contact between the heating cassette substrate and the heating block pennits a highly efficient thermal transfer.
  • the slide was then washed six times with 350 ⁇ l of deionized water.
  • the remaining reactive aldehyde groups were removed from the slide by washing the slide six times with 350 ⁇ l of Sodium Borohydrate (0.4 g NaBFLf, lO ls 100% ethanol, 30mls of PBS) followed by six washes with 350 ⁇ l of deionized water.
  • Synthetic single stranded DNA oligonucleotide 47mer bipartite were synthesized specific for a polymorphism in the Variable Number of Tandem Repeats (VNIR) of the human genome at the loci D1S80.
  • VNIR Variable Number of Tandem Repeats
  • the specific polymo ⁇ hism identified was at the third position with a substitution of adenine for guanine.
  • sequence analysis has revealed many more polymorphic sites within the D1S80 locus.
  • D1S80 consists of a 16 base pair repeat with 29 alleles ranging in size from 369 to 800 base pairs corresponding to 14 and 41 repeats, respectively.
  • the dry bipartites with a sequence of:

Abstract

The present invention concerns a method to improve detection or quantification of a genetic sequence in a genetic sample using a bipartite probe. A bipartite probe is made of a nucleic acid binding sequence capable of hybridizing a target genetic sequence and a binding probe sequence capable of hybridizing to a detectable amplification molecule through a nucleic acid sequence capable of hybridizing to the binding probe sequence of the bipartite probe. The amplification molecule (6) can be a dendriver that includes a label in its core and/or on any of its arms. Moreover, a secondary signal generation molecule (11) may also be added to the mixture to further increase signal. Similarly, tertiary (20) and quaternary (30), etc. amplification molecules may successively be added to yield increase signal.

Description

DETECTION OF GENETIC SEQUENCES USING A BIPARTITE PROBE
CROSS-REFERENCED TO RELATED APPLICATIONS This application is a continuation-in-part of U.S. Patent Application 09/945,952 filed
September 4, 2001. The entire disclosure of which is hereby incorporated by reference.
BACKGROUND OF THE INVENTION
Field of the Invention: This invention relates to a method of detection or quantitation of genetic sequences in a sample of DNA using a bipartite probe and more specifically using additional amplification molecules to enhance the detectable signal.
Description of the Related Art: Different techniques may be employed in order to label nucleic acid probes. Both direct labeling techniques and indirect labeling have been traditionally used to detect target genetic sequences. Traditionally, indirect labeling techniques use a probe genetic sequence that binds to the selected target genetic sequence that has been modified to contain a specified epitope for an antibody - antigen reaction. The indirect methodology is described in U.S. Patents 5,731,158; 5,583,001; 5,196,306 and 5, 182,203 (hereby specifically incorporated by reference). In the direct labeling technique the labeled probe hybridizes to a target genetic sequence and is detectable. The probe will be directly modified to contain at least one fluorescent, radioactive or staining molecule per probe, such as cyanine dye, Alexa dye, horseradish peroxidase (HRP) or any other fluorescent signal generation reagent. The fluorescent signal generation reagent includes, for example, Cyanine, Alexa, Texas Red, FITC, DTAF and FAM. FAM is a fluorescein bioconjugate made of carboxyfluorescein succinimidyl ester (e.g. 5-FAM (Molecular Probes, Eugene, OR). DTAF is a fluorescein dichlorotriazine bioconjugate.
The applications for this invention mirror that of PCR and extend further. Any application that requires any detection of specific genetic elements could benefit from this invention. Areas where PCR is not acceptable because of enzymatic difficulties (extension difficulties) dNTP quality, thermocycling nuances, stringency problems would certainly benefit. Traditionally, Southern Blots are used as an alternative assay when PCR proves to be unsuitable.
The most important feature that differentiates this detection technology from PCR is that there is no physical reproduction of the genetic material of interest. The new methodology detects the presence genetic material from the original source DNA.
BRIEF SUMMARY OF THE INVENTION
The present invention is a process which indirectly detects or quantitates a target genetic sequence in any genetic sample using a bipartite probe. A bipartite probe includes a probe genetic sequence capable of hybridizing with the target genetic sequence and an additional nucleic acid binding probe sequence beyond the probe genetic sequence. Bipartite probes are hybridized with both the target genetic sequence in the DNA sample and amplification probe molecules. Moreover, secondary signal generation molecules may also be added to the mixture to further increase signal. Additional, tertiary and quaternary etc. amplification molecules may successively be added to yield increase signal.
This invention provides a method for detection or quantitation of a target genetic sequence in a genetic sample an assay which involves using a bipartite probe and at least one detectable amplification molecule. A bipartite probe has a nucleic acid binding sequence capable of hybridizing the target genetic sequence in a sample of DNA and a binding probe sequence capable of hybridizing with a nucleic acid sequence of a detectable amplification molecule. An amplification molecule has a nucleic acid sequence capable of hybridizing the binding probe sequence of the bipartite probe. The amplification probe is detectable by a variety of methods.
More specifically, this invention provides a method for detection or quantitation of a target genetic sequence in a genetic sample with an assay which involves using: a bipartite probe having a target nucleic acid binding sequence capable of hybridizing the target genetic sequence and an nucleic acid binding probe sequence capable of hybridizing with a nucleic acid sequence of a primary detectable amplification molecule and a primary detectable amplification molecule having a nucleic acid sequence capable of hybridizing the binding probe sequence of the bipartite probe.
Additionally, this invention provides a method to increase signal strength in an assay for a target genetic sequence in a genetic sample involving the steps of: hybridizing at least one detectable amplification molecule with a bipartite probe in a hybridization solution, the bipartite probe having a target nucleic acid binding sequence capable of hybridizing the target genetic sequence and a binding probe sequence capable of hybridizing with a nucleic acid sequence of at least one detectable amplification molecule. Similarly, this invention provides a method to increase signal strength in an assay for a target genetic sequence in a genetic sample involving the steps of: hybridizing primary and secondary amplification molecules in a hybridization solution and adding a bipartite probe." The bipartite probe having a target nucleic acid binding sequence capable of hybridizing the target genetic sequence and a binding probe sequence capable of hybridizing with a nucleic acid sequence of at least one detectable amplification molecule.
Additionally, this invention provides a method of forensic analysis for a target nucleic acid sequence involving the steps of: isolating human genomic DNA; immobilizing the human genomic DNA on a flat substrate; hybridizing the human genomic DNA with a bipartite probe having a target nucleic acid binding sequence capable of hybridizing the target genetic sequence and a binding probe sequence capable of hybridizing with a nucleic acid sequence of a primary detectable amplification molecule; and a primary detectable amplification molecule having a nucleic acid sequence capable of hybridizing the binding probe sequence of the bipartite probe; detecting the detectable amplification molecule; and correlating the detectable amplification molecule with the target nucleic acid sequence.
BRIEF DESCRIPTION OF THE DRAWINGS
A more complete understanding of the invention and its advantages will be apparent from the following Description of the Preferred Embodiment(s) taken in conjunction with the accompanying drawings, wherein: FIG. 1 is an illustration of the present method.
FIG. 2 is a graph showing percent formamide vs negative change in temperature.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT
The present invention provides a method for discriminating a genetic sequence using a bipartite probe to localize an amplification molecule. All patents, patent applications and articles discussed or referred to in this specification are hereby incorporated by reference.
The following terms and acronyms are used throughout the detailed description: 1. Definitions complementary - chemical affinity between nitrogenous bases as a result of hydrogen bonding. Responsible for the base pairing between nucleic acid strands. Klug, W.S. and
Cummings, M.R. (1997) Concepts of Genetics. 5th ed., Prentice-Hall, Upper Saddle River,
NJ. (hereby incorporated by reference) dendrimer - synthetic 3-dimensional polymer macromolecule that is prepared from simple branched monomer units. The functionality of the macromolecule can be controlled and varied. DNA (deoxyribonucleic acid) - The molecule, that encodes genetic information. DNA is a double-stranded molecule held together by weak bonds between base pairs of nucleotides.
The four nucleotides in DNA contain the bases: adenine (A), guanine (G) cytosine (C), and thyrnine (T). In nature, base pairs form only between A and T and between G and C; thus the base sequence, of each single strand can be deduced from that of its partner. genome - all the genetic material in the chromosomes of a particular organism; its size is generally given as its total number of base pairs. genomic DNA - all of the genetic information encoded in a cell. Lehninger, A.L., Nelson, D.L. Cox, M.M. (1993) Principles of Biochemistry, 2nd ed., Worth Publishers, New York, NY. (hereby incorporated by reference) genotype - genetic constitution of an individual cell or organism. microarray imager - is a reader used to detect samples bound or affixed to a flat substrate. microarray technology ~ is a hybridization-based process that allows simultaneous quantitation of many nucleic acid species, has been described (M. Schena, D. Shalon, R. W. Davis, and P.O. Brown, "Quantitative Monitoring Of Gene Expression Patterns With
A Complementary DNA Microarray," Science, 270(5235), 467-70, 1995; J. DeRisi, L.
Penland, P.O. Brown, M.L. Bittner, P.S. Meltzer, M. Ray, Y, Chen, Y.A. Su, and J.M.
Trent, "Use Of A Cdna Microarray To Analyze Gene Expressions Patterns hi Human
Cancer," Nature Genetics, 14(4), 457-60 ("DeRisi"), 1996; M. Schena, D. Shalon, R. Heller, A Chai, P.O. Brown, and R.W. Davis, "Parallel Human Genome Analysis:
Microarray-Based Expression Monitoring Of 100 Genes," Proc. Natl. Acad. Sci. USA.,
93(20), 10614-9, 1996) hereby incorporated by reference. This technique combines robotic spotting of small amounts of individual, pure nucleic acids species on a glass surface, hybridization to this array with multiple fluorescently labeled nucleic acids, and detection and quantitation of the resulting fluor tagged hybrids with a scanning confocal microscope. This technology was developed for studying gene expression. recombinant DNA - A combination of DNA molecules of different origin that are joined using recombinant DNA technologies. substrate - Any three dimensional material to which sample or probe may be deposited that may have reactive groups to aid in attachment. target genetic sequence - includes a transgenic insert, a selectable marker, recombinant site or any gene or gene segment.
With reference to FIG. 1, the present invention is a process which indirectly detects or quantitates a target genetic sequence in any genetic sample 10. The genetic sample 10 can include genomic DNA, PCR amplicons, total RNA, mRNA, mitochondrial DNA, cDNA, plamid DNA, cosmid DNA and chloroplastic DNA. A bipartite probe 1 includes a target nucleic acid binding sequence 2 capable of hybridizing with the target genetic sequence 3 and an additional nucleic acid binding probe sequence 4 adjacent to the target nucleic acid binding sequence 2. A bipartite probe 1 is hybridized with both the genetic sample 10 including the target genetic sequence 3 and a detectable amplification molecule 6. The detectable amplification molecule 6 includes a capture probe sequence 5 that is a nucleic acid sequence capable of hybridizing with the nucleic acid binding probe sequence 4 of the bipartite probe 1. An amplification in molecule is any element which has the capacity to be detected while bound to a target. A nucleic acid sequence attached to an amplification molecule can be referred to as a capture arm. The capture probe sequence 5 is an example of a capture arm. A capture arm is preferably about 31 bases in length, but can range from about 16 to 90 bases in length. A capture arm to be capable of hybridization should be substantially linear in confirmation.
The1 primary detectable amplification molecule 6 can be a dendrimer that includes a label in its core or more commonly the label is on the dendrimer arms. The primary detectable amplification molecule 6 can also be a less branched or linear labeled or unlabeled oligonucleotides that can generate signal and/ or facilitate the attachment of other labeled molecules. By way of example intermediary oligonucleotides may be hybridized to either the capture probe sequence or the binding probe sequence. Subsequently, this intermediary would bind to its remaining target. These intermediary oligonucleotides would not change the basic and novel aspects of the claimed method.
Moreover, a secondary signal generation molecule may also be added to the hybridization mixture to further increase detectable signal. Similarly, tertiary 20 and quaternary 30 etc. amplification molecules may successively be added to yield increase signal.
A plurality of nucleic acid binding sequences 7 and 13 can be attached to the primary amplification probe molecule 6. These nucleic acid binding sequence must have a specific affinity for the capture arm of another amplification probe molecule. The number of bases that compose the nucleic acid binding sequence can vary based on the size of the genome under study. The probe binding sequence 7 is capable of hybridizing with a single stranded genetic sequence 8 that includes a signal generating means 9. The single stranded genetic sequence 8 is hybridized to one of the capture arms of the primary detectable amplification molecule 6. This signal generating means 9 can include various labels. The label can be enzymes, radioactive isotopes, flurogenic, chemiluminescent or electrochemical materials, or members of a specific binding pair such as biotin-avidin, biotin-streptavidin, folic acid-folate binding proteins. Additionally, examples of covalent binding pairs include sulfhydryl reactive groups such as maleimides and haloacetyl derivatives and amine reactive groups such as isothio cynontes, succinimidyl esters, sulfonyl halides, and coupler esters, sulfonyl halides, and coupler dyes such as 3-methyl-2-benzothiazolinone hydrazone (MBTH) and 3-(dimethyl- amino) benzoic acid. The nucleic acid binding sequence 13 is one of the capture arms of the primary amplification probe molecule 6.
Additionally, a secondary detectable amplification molecule 8 and 11 can be used to further amplify the signal. The secondary amplification molecule 11 can be a secondary signal generating dendrimer with nucleic acid binding sequences 12 and 14. The nucleic acid binding sequences 12 and 14 are the capture arms of the secondary detectable amplification molecule 11. More specifically, the nucleic acid binding sequence 13 is capable of hybridizing with a nucleic acid binding sequence 12 attached to the secondary detectable amplification molecule 11. The nucleic acid binding sequence 12 can be referred to as the capture arm of the secondary detectable amplification molecule 11. It has been discovered that the linearity of the nucleic acid binding sequence 12 of the secondary genetic sequence attached to the secondary detectable amplification molecule 11 is a factor in detectable signal strength. Similarly, the linearity or lack of secondary structures is important for all nucleic acid sequences in the amplification reaction.
Additionally, to further increase signal strength a tertiary detectable amplification molecule 20, such as a tertiary signal generating dendrimer can be subsequently added to the hybridization solution. The tertiary amplification molecule 20 includes a nucleic acid binding sequence 24 that is capable of hybridizing with a nucleic acid binding sequence 14 attached to the secondary detectable amplification molecule 11. The nucleic acid binding sequences 24 and 26 of the tertiary amplification molecule 20 are the capture arms of the tertiary detectable amplification molecule 20. The tertiary detectable amplification molecule 20 also includes a nucleic acid sequence 22 that is capable of hybridizing with a nucleic acid sequence 32 attached to a quaternary detectable amplification molecule, such as a quaternary detectable amplification molecule 30. The quaternary detectable amplification molecule has a nucleic acid sequence 34 that is capable of binding an additional amplification molecule. The nucleic acid binding sequences 34 and 32 of the quaternary detectable amplification molecule 30 are the capture arms of the quaternary detectable amplification molecule 30. Additional signal generating molecules can be added until the amount of quantitated signal exceeds the maximum values the detection instrument can record.
For example, the nucleic acid binding probe sequence 4 of the bipartite probe 1 may have reverse compliment sequence as the 5' end of reverse transcriptase. The bipartite probe 1 would contain the binding sequence of:
5' GGC CGA CTC ACT GCG CGT CTT CTG TCC CGC C - Probe Sequence 3'. (SEQ ID NO: 1)
This nucleic acid binding probe sequence 4 of the bipartite probe 1 is complimentary to the nucleic acid sequence 5 for an amplification dendrimer probe from Genisphere
(Hatfield, PA) 5' CCG GCT GAG TGA CGC GCA GAA GAC AGG GAC G - 3'. (SEQ ID
NO: 2). A fluorescent dye is attached to the dendrimer core and/or the dendrimer arms. This fluorescent dye is a detectable label.
The target nucleic acid binding sequence 2 is specific for the target genetic sequence 3 of the genetic sample 10 respectively. The binding probe sequence 4 of the bipartite probe 1 is free and does not bind to the target genetic sequence 3. Examples of bipartite probes 1, complementary to single copy genes, are shown the table below:
TABLE 1
Figure imgf000011_0001
Examples of bipartite probes 1, complementary to Mouse Major Urinary Protein are shown in the table 2 below. These bipartite probes 1 are made one of the MUP genetic sequences, the target nucleic acid binding sequence 2 and a nucleic acid binding probe sequence 4, that is complementary to the nucleic acid sequence of an amplification molecule, which in this example is a dendrite probe.
TABLE 2
Mup_probel 5'-
GGCCGACTCACTGCGCGTCTTCTGTCCCGCCCTGTGACGTATGATGGATTC AATACA
(SEQ ID NO: 10) Mup probe2
5'GGCCGACTCACTGCGCGTCTTCTGTCCCGCCTCGGCCATAGAGCTCCATC AGCTGGA (SEQ ID NO: 11)
Mup probe 3
5'- GGCCGACTCACTGCGCGTCTTCTGTCCCGCCCTGTATGGATAGGAAGGGATGATG C (SEQ ID NO: 12)
Mup probe4 5'-
GGCCGACTCACTGCGCGTCTTCTGTCCCGCCGGCTCAGGCCATTCTTCATTCTCGG GCCT (SEQ ID NO: 13).
An amplification molecule, such as a dendrimer or tyramide, is introduced. The amplification molecule is bound directly or indirectly to the bipartite. The amplification molecules, such as a dendrite probes, has a nucleic acid capture probe sequence 5 that is complementary to the nucleic acid binding probe sequence 4 of the bipartite probe. The bipartite probe 1 complexed with nucleic acid capture probe sequence 5 of the amplification molecule may be hybridized to a secondary signal generating molecule, such as an additional dendrimers with complimentary sequences or a secondary labeled oligonucleotide such as nucleic acid sequence 8.
Free bipartite probes and excess amplification molecules are removed via several successive wash steps. The bound detectable amplification molecule emits a detectable signal that can have a linear relationship to the number of bound molecules.
One modification of the binding probe sequence 4 of the bipartite probe 1 and/or the capture probe sequences of any of dendrites capture probe sequences include, but not limited to biotinylation. A detectable amplification molecule may have a signal molecule directly attached to it or it may activate or facilitate the attachment of another signal unit. An example of a secondary signal generation element includes but not limited to enzymes and labeled antibodies. Multiple signals units may be used to amplify the signal of the target. The bipartite probe 1, which is composed of the target nucleic acid binding sequence 2 and the binding probe sequence 4, is added to a genetic sample 10, preferably genomic DNA. The target nucleic acid binding sequence 2 of the bipartite probe 1 specifically hybridizes to the target genetic sequence 3 of the genomic DNA sample 10. The nucleic acid binding sequence 5 of the amplification probe molecule 6 specifically hybridizes to the binding probe sequence 4 elements of the bipartite probe 1. In one embodiment the primary detectable amplification molecule 6 is a dendrimer and includes a fluorescent tag that functions as a label in an assay. The signal may further be increased by subsequently adding various forms of secondary, tertiary, quaternary etc signal generating units. In an alternative embodiment the amplification molecules are hybridized together prior to adding the bipartite probe 1. Alternatively, the modification, such as proteins (eg. Biotinylation), may be added to either the binding probe sequence of the bipartite and/or the capture probe sequence of the dendrite. This modification will allow for protein interaction resulting in indirect labeling.
In the preferred embodiment DNA from a genetic sample is immobilized onto a substrate, preferably a glass slide. The substrates typically have a reactive group attached to the surface to facilitate the immobilization. Aldehyde reactive groups covalently coupled to the glass subsequently covalently immobilize the DNA via a dehydration reaction. Typically, to reduce the background signal a Sodium Borohydrate Hydrate solution is added to reduce the unused aldehyde reactive groups to alcohol. The bound DNA is denatured via heating the substrate above 94° C for five minutes. This heating process disrupts the hydrogen bonds between adenine, cytosine, guanine and thymine. A bipartite probe 1 is added to the substrate suspended in a hybridization buffer and covered with a coverslip. The bipartite probe 1 in solution is incubated at 43-55° C for one hour. During this incubation the target nucleic acid genetic sequence 2 of the bipartite probe 1 specifically hybridizes to the target genetic sequence of the sample DNA 10. A three minute wash in 2X Saline Sodium Citrate (SSC) and a one minute wash in 0.2 X SSC removes any unbound bipartite. Amplification molecules are suspended in a hybridization buffer and added to the substrate and coverslipped. The amplification molecules in solution are incubated at 50 - 55° C for one hour. During this incubation the binding probe sequence of the bipartite probe 1 specifically hybridizes to the capture arm of the amplification probe molecule. A three minute wash in 2X SSC and a one minute wash in 0.2 X SSC removes any unbound amplification probe molecules. The secondary signal generating dendrite probe, has a nucleic acid capture probe sequence that is complementary to the capture probe sequence of the primary detectable amplification probe 6. The secondary signal generating dendrite probes are suspended in a hybridization buffer. The "secondary signal generating dendrite" probe in solution are incubated at 50-55°C for one hour. During this incubation the capture arm sequence of the secondary signal generating dendrite probe specifically hybridizes to the capture arm of the amplification probe molecule. A 15 minute wash in 2X SSC, 0.2% SDS, followed by three five minute washes in 2X SSC and a one minute wash in a 0.2X SSC removes any unbound molecules, hi the preferred embodiment amplification molecules are added sequentially, however prehybridizing two or more amplification molecules together before hybridizing to the binding probe sequence of the bipartite is also contemplated.
A secondary signal generating dendrite probe serving as a secondary amplification molecule are suspended in a hybridization buffer. The secondary signal generating dendrite probe, has a nucleic acid binding sequence that is complementary to the nucleic acid binding sequence of the primary detectable amplification molecule 6. The bipartite probe 1 is complexed with capture probe sequences of the primary amplification molecule which may be complexed to a secondary amplification molecule.
Certain factors are considered when designing the capture arms as used in this invention. The first consideration is to make sure the sequence is specific for the genetic target in the genome under study. The four bases (adenine, thymine, guanine and cytosine) raised to the number of bases in the sequence (eg. 4πumber of ases) should be a number larger than the number of bases in the genome being studied. By way of example, the number of bases in the mouse genome is 3.0 x 109. For consideration of a bipartite 's target nucleic acid binding sequence being 16 bases in length, the. calculation would be 416 which is 4.29 x 109. Whereas a target nucleic acid binding sequence of 15 bases would yield 415 which is 1.07 x
109. This is less than 3.0 x 109 rendering 15 bases inadequate to be discriminatory for the mouse genome.
The optimal hybridization temperature is dependent on the length and composition of the oligonucleotide. The melting temperature of each element determines the optimal hybridization of both the target nucleic acid binding sequence and the nucleic acid binding probe sequence of the bipartite probe. Each melting temperature is determined independently.
By way of example the melting temperature of a 20mer target nucleic acid binding sequence is 68.3°C. A 20mer is long enough to confer specificity to the eukaryotic genome of 3.0xl09 base pairs. The optimal hybridization temperature is 20-25°C lower than 68.3°C resulting in a 43.0°C hybridization temperature with a tradition buffer such as (1) 0.25
NaPO4, 4.5%SDS ImM EDTA, 1XSSC, 2X Denhardt's solution or (2) 2XSSC, 1%SDS.
The same 20mer target nucleic acid binding sequence with the 68.3°C melting temperature in a 40% formamide buffer has a remarkably different optimal hybridization temperature. In addition to the lower temperature of 20-25°C and additional decrease of 20°C is required resulting in an optimal hybridization temperature of 23.0°C.
The nucleic acid binding probe sequence 4 of the bipartite probe 1 is also determined in the same fashion. The nucleic acid binding probe sequence 4 for a 3 lmer has a melting temperature of 94.0°C. For traditional hybridization buffers 20-25°C below the melting temperate results in an optimal temperature of 70.0°C. i a 40% formamide solution the optimal hybridization temperature decreases 20°C resulting in a hybridization temperature of 50.0°C.
A 16mer target nucleic acid binding probe sequence 4 is' the minimum number of bases to confer specificity to the eukarotic genome. A 16mer has a melting temperature of 54.0°C. Traditional, hybridization buffers optimally hybridizing at 20°C less than the melting temperature yields optimal results at 29.0°C. Whereas a 40% formamide buffer requires an additional 20°C decrease in temperature to optimal hybridize at 9.0°C.
The nucleic acid binding probe sequence 4 for a 3 lmer has a melting temperature of 94.0°C. 20-25°C below the melting temperate is the traditional range for optimal hybridization. For the 3 lmer a traditional hybridization buffer has an optimal hybridization temperature of 70.0°C. In a 40% formamide solution the optimal hybridization temperature decreases 20°C resulting in a hybridization temperature of 50.0°C-
The number of bases to confer specificity to a prokaryote with a genome of eighteen thousand base pairs is less than the number of bases to be discriminatory for the eukaryotic genome. As an example, a 8mer has enough bases to be discriminatory for a genome of eighteen thousand base pairs. An 8mer target nucleic acid binding sequence 2 will have a low melting temperature due to few number of bases. An 8mer with a melting temperature of 27.0°C in a traditional buffer has a realized optimal hybridization at 2.0°C. Because of the 20°C drop in temperature below that of a traditional buffer, a formamide hybridization of an 8mer is not possible in formamide.
A 13mer target nucleic acid binding sequence 2 is long enough to confer specificity to a prokaryotic genome of eighteen thousand base pairs. A 13mer with a melting temperature of 45.0°C will optimally hybridize in a traditional buffer at 19.0°C. Whereas it is possible to optimally hybridize in 40% formamide at 0°C.
Therefore the preferred number of bases for the target nucleic acid binding sequence 2 is 16-20 bases for the eukarotic genome. Whereas by contrast the preferred length of the target nucleic acid binding sequence 2 is 8-13 bases for prokaryotes with a genome of 18,000 base pairs. The preferred number of bases for the nucleic acid binding probe sequence 4 is for eukaryotes and prokaryotes is the same. A preferred length of 31 bases confers specifically to its compliment.
A sequence search, known as a blast from public internet sites such as National Center for Biotechnology Information (NCIB) available at http://www.ncbi.nlm.nih.gov/ or private databases such as Celera's (Rockville, MD) should be performed. A blast of all known sequences for a particular species helps ensure specificity. If a blast reveals that a particular sequence exists in the genome then no preference will be appreciable between the target sequence and the endogenous sequence.
Because of the hydrogen bonding between adenine/thymine and guanine/cytosine, two and three bonds respectively, secondary structures can form. The secondary structures include stem loop structures and homodimers. Stem loop structures form because of the affinity of one region of the bipartite for another region of the same bipartite, specifically between the guanine and cytosine residues. Whereas homodimer show an affinity for anther molecule of the same species. hi order to provide a capture arm capable of hybridization both of these 'secondary structures should be eliminated in a variety of ways. Simply selecting an alternative sequence that is not rich in guanine and cytosine often is all that is needed to produce a species with no stable secondary structures. If the sequence is sufficiently long enough, it is possible to delete the portion of the arm that participates in the formation of the secondary structure as long as the remaining element is sufficient for specific hybridization. The application of heat sufficient to overcome the secondary structures is highly effective. However, the temperature to optimally hybridize should be higher than the temperature to reduce secondary structures. Secondary structures may also be reduced by the substitution of bases. Inosine is a nucleoside that can be substituted for a base participating in the formation of a secondary structure thereby destabilizing the structure. Moreover, substituting a base that forms a mismatch will also destabilize the secondary structures. Although, there must be sufficient base pairing between the capture arms and the target to yield adequate hybridization in spite of the mismatch. By way of example, the 29th base, which is guanine, was substituted with adenine in order to disrupt the stem loop structure in a secondary signal generating dendrimer. This base mismatch destabilized the stem loop structure, which then allows nucleic acid arm to participate in a hybridization reaction. The melting temperature to disassociate the hairpin structure because of the base mismatch was 7°C as opposed to 70°C for the perfect match. However, the mismatch does not prevent hybridization between amplification molecule and the secondary signal generating dendrimer.
The secondary signal generating dendrimer had a capture sequence of: 5' - GGC CGA CTC ACT GCG CGT CTT CTG TCC CAC C -3' (SEQ ID NO: 14) which had the following characteristics: TABLE 3
Figure imgf000019_0001
STEM LOOP STRUCTURE:
CTCAGCCGG 5' (SEQ ID NO: 15)
< II
ACTGCGCGTCTTCTGTCCCACC 3' (SEQ ID NO: 16)
G = 0.5 kcal/mol loop Tm = 7°C HOMODIMER:
5' GGCCGACTCACTGCGCGTCTTCTGTCCCACC 3' (SEQ ID NO: 17)
3' CCACCCTGTCTTCTGCGCGTCACTCAGCCGG 5' (SEQ ID NO: 18) Homodimer Tm = 32.7°C
The sequence 5' GGC CGA CTC ACT GCG CGT CTT CTG TCC CGC C 3' (SEQ ID NO: 19) is the perfect match for the capture probe sequence of the amplification molecule however it has the following characteristics:
TABLE 4
Figure imgf000019_0002
STEM LOOP STRUCTURE:
CTTCTGCGCGTCACTCAGCCGG 5' (SEQ ID NO:20)
< III
TGTCCCGCC 3' (SEQ ID NO:21)
I
G = -2.4 kcal/mol loop Tm = 70°C
HOMODIMER: 5' GGCCGACTCACTGCGCGTCTTCTGTCCCGCC 3' (SEQ ID NO:22)
3' CCGCCCTGTCTTCTGCGCGTCACTCAGCCGG 5' (SEQ ID NO:23)
Homodimer Tm = 34.0°C
Another alternative for destabilizing the loop structure and affecting the1 optimal hybridization temperature is the addition of a chemical agent such as formamide. Formamide changes the melting temperature and expected optimal hybridization temperate One degree Celsius for every 2% formamide added beyond the traditionally accepted optimal hybridization range of 20-25° C below the melting temperature. Therefore adjusting the percentage can dramatically affect the thermal requirements for a successful reaction.
The Binding Probe Sequence of the bipartite which is: 5' - GGC CGA CTC ACT GCG CGT CTT CTG TCC CGC C -3' (SEQ ID NO:24) with the following characteristics:
TABLE 5
Figure imgf000021_0001
STEM LOOP STRUCTURE:
CTTCTGCGCGTCACTCAGCCGG 5' (SEQ ID NO:25)
< III
TGTCCCGCC 3' (SEQ ID O:26)
G = -2.4 kcal/mol loop Tm = 70°C
HOMODIMER:
5' GGCCGACTCACTGCGCGTCTTCTGTCCCGCC 3' (SEQ ID NO:27)
3' CCGCCCTGTCTTCTGCGCGTCACTCAGCCGG 5' (SEQ ID NO:28)
Homodimer Tm = 34.0°C
Example 1: Bipartite Probe and Single Amplification Probe Molecule
Synthetic single stranded DNA oligonucleotides 51mers bipartites were synthesized by hivitrogen (Carlsbad, CA). The dry bipartites were rehydrated with deionized water at a concentration of 200 μM. The bipartites mixture consisting of lμl of bipartite, 4.5 μl of 20xSSC (Saline Sodium Citrate) and 24.5 μl of deionized water was added to the wells of a Whatman (Clifton, NJ) polypropylene 384, 80μl V-bottom wellplate. The bipartites were printed with a SpotBot (Telechem, Sunnyvale, CA) onto Superaldehyde substrates (Telechem, Sunnyvale, CA) in a grid pattern of five columns by six rows. The printed substrate is. loaded into a heating cassette. The heating cassette is composed o a beveled top plate, prefabricated spacers, a metal frame and tension clips. The substrate is lowered into the metal frame and spacers are placed on top of the substrate running lengthwise along the edge. The beveled top plate is then lowered on top of the substrate only separated by the spacers. The metal tension clips are then applied to the heating cassette, which holds the cassette together securely.
The heating cassette is placed on the exterior platform of the heating block. The heating block's exterior surface is thermally controlled by different temperature fluids being perfused by external circulator baths. The contact between the heating cassette substrate and the heating block permits a highly efficient thermal transfer.
The slide was then washed six times with 350μl of deionized water. The remaining reactive aldehyde groups were removed from the slide by washing the slide six times with 350μl of Sodium Borohydrate (0.4 gNaBFLi, lOmls 100% ethanol, 30mls of PBS) followed by six washes with 350μl of deionized water. 4μl of CY3 dendrimer (primaiy detectable amplification Molecule) and 116μl of 40 % Formamide, 4XSSC, 1% SDS, 2X Denhardt's Solution, was incubated at 50°C for 60 minutes. The substrate was washed seven times with 350μl of 2X SSC, 0.2% SDS, followed by eleven 350μl washes in 2X SSC and two 350μl washes in a 0.2X SSC. The slides was dried and scanned at a gain of 255, 200 and 100. The following results from 60 samples demonstrate a single amplification molecule attached to a bipartite and can be used as a baseline for additional amplifications.
TABLE 6
255 200 100
Baseline Baseline Baseline
Position Density Position Density Position Density
1-1:1 6941.05 1 1-1:1 875.48 1 1-1:1 0.33
1-1:2 8346.22 2 1-1:2 1053.07 2 1-1:2 0.28
1-1:3 5868.25 3 1-1:3 658.26 3 1-1:3 1.01
1-1:4 4551.32 4 1-1:4 497.52 4 1-1:4 9
1-1:5 5146.45 5 1-1:5 575.44 5 1-1:5 4.74
1-2:1 1798.24 6 1-2:1 197.07 6 1-2:1 3.99
1-2:2 3528.95 7 1-2:2 641.32 7 1-2:2 4.94
1-2:3 942.91 8 1-2:3 115 8 1-2:3 5.11
1-2:4 886.56 9 1-2:4 96.89 9 1-2:4 12
1-2:5 1076.32 10 1-2:5 122.1 10 1-215 8.92
1-3:1 1372.14 11 1-3:1 149.66 11 1-3:1 9.16
1-3:2 900.74 12 1-3:2 103.67 12 1-3:2 9.55
1-3:3 3606.58 13 1-3:3 412.24 13 1-3;3 4.39
1-3:4 15767.1 14 1-3:4 2431.13 14 1-3:4 7.77
1-3:5 11082.13 15 1-3:5 1418.62 15 1-3:5 0.88
1-4:1 9801.71 16 1-4:1 1232.66 16 1-4:1 9.19
1-4:2 12067.38 17 1-4:2 1466.64 17 1-4:2 7.31
1-4:3 11162.8 18 1-4:3 1500.59 18 1-4:3 6.05
1-4:4 18770.91 19 1-4:4 3066.03 19 1-4;4 2.57
1-4:5 16521.03 20 1-4:5 2376.26 20 1-4:5 7.48
1-5:1 18222.83 21 1-5:1 2551.4 21 1-5:1 0.31
1-5:2 17484.73 22 1-5:2 2576.47 22 1-5:2 0.66
1-5:3 11803.16 23 1-5:3 1483.21 23 1-5:3 0.2
1-5:4 14515.22 24 1-5:4 2174.71 24 1-5:4 0.22
1-5:5 3346.52 25 1-5:5 379.09 25 1-5:5 0.23
1-6:1 17863.92 26 1-6:1 2570.57 26 1-6:1 0.25
1-6:2 14544.42 27 1-6:2 2053.7 27 1-6;2 0.2
1-6:3 12623.67 28 .1-6:3 1787.79 28 1-6:3 0.26
1-6:4 7320.88 29 1-6:4 889.35 29 1-6:4 0.17
1-6:5 14564.03 30 1-6:5 2016.93 30 1-6:5 0.23
2-1:1 987.97 31 2-1:1 106.75 31 2-1 ;1 1.27
2-1:2 1354.89 32 2-1:2 149.03 32 2-1:2 0.4
2-1:3 1871.3 33 2-1:3 200.87 33 2-1:3 2.41
2-1:4 3288.86 34 2-1:4 363.07 34 2-1:4 5.95
2-1:5 5657.32 35 2-1:5 782.71 35 2-1:5 6.52
2-2:1 4965.23 36 2-2:1 568.64 36 2-2:1 6.8
2-2:2 5781.66 37 2-2:2 726.88 37 2-2:2 5.98
2-2:3 4639.2 38 2-2:3 528.22 38 2-2:3 5.43
2-2:4 7146.23 39 2-2:4 906.97 39 2-2:4 5.24
2-2:5 797.15 40 2-2:5 90.35 40 2-2;5 5.25
2-3:1 3339.81 41 2-3:1 417.37 41 2-311 3.43
2-3:2 1965.02 42 2-3:2 204.02 42 2-3:2 1.34
2-3:3 7152.04 43 2-3:3 864.81 43 2-3:3 2.13
2-3:4 10749.06 44 2-3:4 1751.83. 44 2-3:4 2.06
2-3:5 10882.52 45 2-3:5 1821.55 45 2-3:5 1.77
2-4:1 12678.6 46 2-4:1 1919.5 46 2-4:1 7.66
2-4:2 11469.72 47 2-4:2 1743.12 47 2-4:2 7.06
2-4:3 11576.24 48 2-4:3 1632.25 48 2-4:3 6.41
2-4:4 10454.25 49 2-4:4 1546.36 49 2-4:4 4.95 50 2-4:5 11237.03 50 2-4:5 1608.98 50 2-4Ϊ5 3.2
51 2-5:1 9560.81 51 2-5:1 1087.62 51 2-5:1 0.24
52 2-5:2 6008.46 52 2-5:2 633.04 52 2-5:2 0.23
53 2-5:3 8380.78 53 2-5:3 899.31 53 2-5:3 0.22
54 2-5:4 8412.45 54 2-5:4 895.45 54 2-5:4 0.26
55 2-5:5 8094.66 55 2-5:5 840.9 55 2-5:5 0.22
56 2-6:1 16528.55 56 2-6:1 2198.41 56 2-6:1 0.26
57 2-6:2 15772.75 57 2-6:2 2045.09 57 2-6:2 0.22
58 2-6:3 14347.99 58 2-6:3 1881.88 58 2-6:3 0.21
59 2-6:4 10955.43 59 2-6:4 1439.66 59 2-6:4 0.2
60 2-6:5 9306.89 60 2-6:5 1075.13 60 2-6:5 0.18
Mean 8463.18 Mean 1140.04 Mean 3.42
SD 5312.07 SD 800.15 SD 3.32
Min 797.15 Min 90.35 Min 0.17
Max 18770.91 Max 3066.03 Max 12
Range 17973.76 Range 2975.68 Range 11.83
Sum 507791.01 Sum 68402.64 Sum 204.93
Example 2: Bipartite Probe and Multiple Amplification Probe Molecule
Synthetic single stranded DNA oligonucleotides 51mers bipartites were synthesized by Invitrogen (Carlsbad, CA). The dry bipartites were rehydrated with deionized water at a concentration of 200μM. The bipaitites mixture consisting of lμl of bipartite, 4.5μl of 20xSSC (Saline Sodium Citrate) and 24.5μl of deionized water was added to, the wells of a Whatman (Clifton, NJ) polypropylene 384, 80μl V-bottom wellplate. The bipartites were printed with a SpotBot (Telechem, Sunnyvale, CA) onto Superaldehyde substrates (Telechem, Sunnyvale, CA) in a grid pattern of five columns by six rows; The printed substrate is loaded into a heating cassette. The heating cassette is composed of a beveled top plate, prefabricated spacers, a metal frame and tension clips. The substrate is lowered into the metal frame and spacers are placed on top of the substrate running lengthwise along the edge. The beveled top plate is then lowered on top of the substrate only separated by the spacers. The metal tension clips are then applied to the heating cassette, which holds the cassette together securely.
The heating cassette is placed on the exterior platform of the heating block. The heating block's exterior surface is thermally controlled by different temperature fluids being perfused by external circulator baths. The contact between the heating cassette substrate and the heating block permits a highly efficient thermal transfer. The slide was then washed six times with 350μl of deionized water. The remaining reactive aldehyde groups were removed from the slide by washing the slide six times with 350μl of Sodium Borohydrate (0.4 g
NaBFLi, lOmls 100% ethanol, 30mls of PBS) followed by six washes with 350μl of deionized water, lμl of CY3 dendrimer (Amplification Probe Molecule) and 116μl of 40 % Formamide, 4XSSC, 1% SDS, 2X Denhardt's Solution, was incubated at 55°C for 60 minutes. The substrate was washed three times with 350μl of 2X SSC followed by two 350μl washes in 0.2X SSC. 1.5 μl of CY3 secondary signal generating dendrimer with the capture sequence of 5'-GGC CGA CTC ACT GCG CGT CTT CTG TCC CAC C -3' (SEQ ID NO:29) and 114μl of 40 % Formamide, 4XSSC, 1% SDS, 2X Denhardt's Solution, was incubated at 55°C for 60 minutes. The substrate was washed seven times with 350μl of 2X SSC, 0.2% SDS, followed by eleven 350μl washes in 2X SSC and two 350μl washes in a 0.2X SSC to remove any excess dendrimer. The slides was dried and scanned at a gain of 255, 200 and 100. The following results from 60 samples demonstrate an amplification of signal from a secondary signal generating dendrimers hybridized to an amplification probe molecule which in turn is hybridized to a bipartite. The secondary signal enhancement represented indicates a three to seven fold increase in signal over the baseline single bipartite and amplification probe molecule hybridization.
TABLE 7
255 200 100
Enhancer Enhancer Enhancer
Position Density Position Density Position Density
1-1:1 21466.58 1 1-1:1 3284.9 1 1-1:1. 17.33
1-1:2 20608.05 2 1-1:2 2695.86 2 1-1:2 13.7
1-1:3 21356.09 3 1-1:3 2746.01 3 1-1:3 14.09
1-1:4 20785.57 4 1-1:4 3285.38 4 1-1:4 17.17
1-1:5 22079.76 5 1-1:5 2812.97 5 1-1:5 14.46
1-2:1 22249.47 6 1-2:1 3699.86 6 1-2:1 19.92
1-2:2 22943.9 7 1-2:2 3790.91 7 1-2:2 20.61
1-2:3 24759.33 8 1-2:3 3901.18 8 1-≥:3 20.68
1-2:4 23492.35 9 1-2:4 3578.82 9 1-2:4 19.21
1-2:5 24550.58 10 1-2:5 3739.15 10 1-2:5 19.99
1-3:1 25725.09 11 1-3:1 5183.08 11 1-3:1 28.68
1-3:2 25157.78 12 1-3:2 4993.68 12 1-3:2 27.26
1-3:3 24589.76 13 1-3:3 4725.14 13 1-3:3 26.11
1-3:4 25405.29 14 1-3:4 5138.36 14 1-3:4 28.16
1-3:5 26018.43 15 1-3:5 4893.9 15 1-3:5 26.56
1-4:1 25912.36 16 1-4:1 5163.63 16 1-4:1 28.26
1-4:2 25761.34 17 1-4:2 5585.81 17 1-4:2 30.63
1-4:3 26454.03 18 1-4:3 5312 18 1-4:3 29.22
1-4:4 26585.17 19 1-4:4 5299.24 19 1-4:4 29.22
1-4:5 26444.09 20 1-4:5 5237.46 20 1-4:5 28.79
1-5:1 25935.77 21 1-5:1 5609.51 21 1-5:1 30.98
1-5:2 26376.21 22 1-5:2 5850.5 22 1-5:2 32.25
1-5:3 26816.98 23 1-5:3 5333.97 23 1-5:3 29.74
1-5:4 27171.67 24 1-5:4 5443.19 24 1-5:4 30.31
1-5:5 25551.35 25 1-5:5 4786.85 25 1-5:5 26.45
1-6:1 26995.04 26 1-6:1 7323.1 26 1-6:1 41.06
1-6:2 27327.11 27 1-6:2 5566.61 27 1-J3:2 30.98
1-6:3 27168.12 28 1-6:3 5778.9 28 1-6:3 31.72
1-6:4 27293.74 29 1-6:4 5766.32 29 1-6:4 32.06
1-6:5 26982.91 30 1-6:5 5813.67 30 1-6:5 32.11
2-1:1 17940.81 31 2-1:1 2518.41 31 2-τ:1 12.85
2-1:2 18939.96 32 2-1:2 2346.19 32 2-1:2 11.51
2-1:3 20290.34 33 2-1:3 2839.18 33 2-1:3 14.73
2-1:4 20495.33 34 2-1:4 2565.22 34 2-1:4 13
2-1:5 21312.59 35 2-1:5 3200.48 35 2-1:5 16.73
2-2:1 20425.43 36 2-2:1 2900.59 36 2-2:1 15.03
2-2:2 21927.46 37 2-2:2 2797.39 37 2-2:2 14.28
2-2:3 19091 38 2-2:3 2501.09 38 2-2:3 12.87
2-2:4 21339.34 39 2-2:4 2635.29 39 2-2:4 13.43
2-2:5 21733.1 40 2-2:5 2670.43 40 2-2:5 13.84
2-3:1 24060.99 41 2-3:1 3765 41 2-3:1 20.08
2-3:2 22036.33 42 2-3:2 3211.25 42 2-3:2 17.04
2-3:3 22234.28 43 2-3:3 3303.46 43 2-3:3 17.39
2-3:4 23778.08 44 2-3:4 3371.82 44 2-3:4 17.9
2-3:5 24821.74 45 2-3:5 3442.73 45 2-3:5 18.32
2-4:1 25990.85 46 2-4:1 5254.61 46 2- :1 29.53
2-4:2 26428.6 47 2-4:2 4693.78 47 2-4:2 25.88
2-4:3 25165.79 48 2-4:3 4490.97 48 24:3 24.27
2-4:4 29413.18 49 2-4:4 4836.14 49 2-4:4 26.12 50 2-4:5 25478.91 50 2-4:5 4184.69 50 2-4:5 23.08
51 2-5:1 26476.14 51 2-5:1 5893.81 51 2-5:1 32.47
52 2-5:2 26481.86 52 2-5:2 4790.09 52 2-5:2 26.53
53 2-5:3 26520.58 53 2-5:3 4887.64 53 2-5:3 26.52
54 2-5:4 26629.56 54 2-5:4 4953.05 54 2-5:4 26.85
55 2-5:5 25985.88 55 2-5:5 4656.07 55 2-5:5 25.26
56 2-6:1 27187.69 56 2-6:1 6415.64 56 2-6:1 35.66
57 2-6:2 27032.69 57 2-6:2 5974.1 57 2-6:2 32.77
58 2-6:3 27004.19 58 2-6:3 5712.7 58 2-6:3 31.69
59 2-6:4 30952.17 59 2-6:4 6182.59 59 2-6:4 34.78
60 2-6:5 26584.3 60 2-6:5 5496.89 60 2-6:5 30.62
Mean 24562.05 Mean 4413.85 Mean 23.98
SD 2771.98 SD 1246.1 SD 7.35
Min 17940.81 Min 2346.19 Min 11.51
Max 30952.17 Max 7323.1 Max 41.06
Range 13011.36 Range 4976.91 Range 29.55
Sum 1473723.1 Sum 264831.28 Sum 1438.78
Example ; 3: ] Bipartite Probe and Single Amplification Probe Molecule for Forensic
Analysis
200ng/μl of human genomic DNA was isolated using Sambrook, J., Fritsch, E.F., and Maniatis, T., in Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press, NY, Vol. 1, 2, 3 (1989). 4.5μl of 20xSSC (Saline Sodium Citrate) and 24.5μl of human genomic DNA was added to the wells of a Whatman (Clifton, NJ) polypropylene 384, 80μl V-bottom wellplate and mixed. The genomic DNA was printed with a SpotBot (Telechem, Sunnyvale, CA) onto Superaldehyde substrates (Telechem, Sunnyvale, CA) in a grid pattern of five columns by six rows. The printed substrate were dried and loaded into a heating cassette. The heating cassette is composed of a beveled top plate, prefabricated spacers, a metal frame and tension clips. The substrate was lowered into the metal frame and spacers were placed on top of the substrate running lengthwise along the edge. The beveled top plate was then lowered on top of the substrate only separated by the spacers. The metal tension clips were then applied to the heating cassette, which held the cassette together securely. The heating cassette was placed on the exterior platform of the heating block. The heating block's exterior surface is thermally controlled by different temperature fluids being perfused by external circulator baths. The contact between the heating cassette substrate and the heating block pennits a highly efficient thermal transfer. The slide was then washed six times with 350μl of deionized water. The remaining reactive aldehyde groups were removed from the slide by washing the slide six times with 350μl of Sodium Borohydrate (0.4 g NaBFLf, lO ls 100% ethanol, 30mls of PBS) followed by six washes with 350μl of deionized water.
Synthetic single stranded DNA oligonucleotide 47mer bipartite were synthesized specific for a polymorphism in the Variable Number of Tandem Repeats (VNIR) of the human genome at the loci D1S80. The specific polymoφhism identified was at the third position with a substitution of adenine for guanine. However, sequence analysis has revealed many more polymorphic sites within the D1S80 locus. D1S80 consists of a 16 base pair repeat with 29 alleles ranging in size from 369 to 800 base pairs corresponding to 14 and 41 repeats, respectively. The dry bipartites with a sequence of:
5'-GGC CGA CTC ACT GCG CGT CTT CTG TCC CGC C GAA GAC CAC CGG CAA G- 3' (SEQ ID NO:30) was rehydrated with deionized water at a concentration of 200 μM. 2μl of 200μm bipartite was added to 118μl of 0.25 NaPO4, 4.5% SDS, ImMEDTA, 1XSSC, 2X Denhardt's Solution which was added to the substrate and incubated at 45°C for 60 minutes. The substrate was washed three times with 350μl of 2X SSC followed by two 350μl washes in 0.2X SSC. 9μl of CY3 Primary Detectable Amplification Molecules and lllμl of 40 % Formamide, 4XSSC, 1% SDS, 2X Denhardt's Solution, was incubated at 53°C for 60 minutes. The substrate was washed seven times with 350μl of 2X SSC, 0.2%o SDS, followed by eleven 350μl washes in 2X SSC and two 350μl washes in a 0.2X SSC to remove any excess dendrimer. The slides was dried and scanned. The detectable amplification molecule was detected and correlated with the presence or the amount of the said target nucleic acid sequence.
Although the present invention has been described and illustrated with respect to a preferred embodiment and a preferred use thereof, it is not to be so limited since modifications and changes can be made therein which are fully within the scope of the invention.

Claims

We claim:
1. A method for detection or quantitation of a target genetic sequence ϊn a genetic sample an assay which comprises using:
(1) a bipartite probe consisting essentially of a target nucleic acid binding sequence capable of hybridizing said target genetic sequence and an nucleic acid binding probe sequence capable of hybridizing with a nucleic acid sequence of a primary detectable amplification molecule; and
(2) a primary detectable amplification molecule consisting essentially of a nucleic acid sequence capable of hybridizing the binding probe sequence of said bipartite probe.
2. The method of claim 1 wherein said primary amplification molecule further consists of a nucleic acid binding sequence capable of hybridizing a labeled genetic sequence.
3. The method of claim 2 wherein said labeled genetic sequence is a single stranded oligonucleotide.
4. The method of claim 2 wherein said primary detectable amplification molecule further consists of a nucleic acid sequence capable of hybridizing to a secondary detectable amplification molecule.
5. The method of claim 4 wherein said secondary detectable amplification 'molecule is a dendrimer.
6. The method of claim 1 wherein said primary detectable amplification molecule is a dendrimer.
7. The method of claim 1 wherein said genetic sample is genomic DNA
8. The method of claim 2 wherein the label of said labeled genetic sequence is selected from the group consisting of enzymes, radioactive isotopes, flurogenic, chemiluminescent, electrochemical materials and members of a specific binding pair.
9. The method of claim 1 wherein said method further consists of sequentially hybridizing a second detectable amplification molecule.
10. The method of claim 9 wherein said method further consists of sequentially hybridizing a third detectable amplification molecule.
11. The method of claim 10 wherein said method further consists of sequentially hybridizing a fourth detectable amplification molecule.
12. The method of claim 1 wherein the said target nucleic acid binding sequence for a eukaryotic organism ranges from between 16 to 20 bases.
13. The method of claim 1 wherein the said target nucleic acid binding sequence for a prokaryotic organism ranges for between 8 to 13 bases.
14. The method of claim 1 wherein the said nucleic acid binding sequence is 31 bases.
15. The method of claim 1 wherein the said nucleic acid binding probe sequence of the secondary amplification molecule is 31 bases in length.
16. A method to increase signal strength in an assay for a target genetic seq ence in a genetic sample comprising: hybridizing at least one detectable amplification molecule with a bipartite probe in a hybridization solution, said bipartite probe consisting essentially of a target nucleic acid binding sequence capable of hybridizing said target genetic sequence and a binding probe sequence capable of hybridizing with a nucleic acid sequence of at least one detectable amplification molecule.
17. The method of claim 16 wherein said at least one detectable amplification molecule includes at least one capture arm.
18. The method of claim 17 wherein said at least one capture arm is between 16 to 90 bases.
19. The method of claim 16 wherein said at least one detectable amplification molecule is a dendrimer.
20. A method to increase signal strength in an assay for a target genetic sequence in a genetic sample comprising: hybridizing primary and secondary detectable amplification molecules in a hybidization solution and adding a bipartite probe said bipartite probe consisting essentially of a target nucleic acid binding sequence capable of hybridizing said target genetic sequence and a binding probe sequence capable of hybridizing with a nucleic acid sequence of at least one detectable amplification molecule.
21. The method of claim 20 wherein said primary and secondary detectable ' amplification molecules are dendrimers.
22. The method of claim 20 wherein said detectable amplification molecules include at least one capture arm.
23. The method of claim 20 wherein said capture arms are between 16 to 9Q bases.
24. A method of forensic analysis for a target nucleic acid sequence comprising: (a) isolating human genomic DNA;
(b) immobilizing said human genomic DNA on a flat substrate;
(c) hybridizing said human genomic DNA with a bipartite probe consisting essentially of a target nucleic acid binding sequence capable of hybridizing said target genetic sequence and a binding probe sequence capable of hybridizing with a nucleic acid sequence of a primary detectable amplification molecule; and a primary detectable amplification molecule consisting essentially of a nucleic acid sequence capable of hybridizing the binding probe sequence of said bipartite probe;
(d) detecting said detectable amplification molecule; and (e) correlating said detectable amplification molecule with said target nucleic acid sequence.
25. The method of claim 24 wherein said target nucleic acid sequence is polymorphism in the variable number of tandem repeats of the human genome.
26. The method of claim 24 wherein said target nucleic acid binding sequen'ce capable of hybridizing said target genetic sequence comprises SEQ ID NO:30.
PCT/US2002/027865 2001-09-04 2002-09-03 Detection of genetic sequences using a bipartite probe WO2003020985A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/945,952 US7011943B2 (en) 2000-09-06 2001-09-04 Method for detecting a designated genetic sequence in murine genomic DNA
US09/945,952 2001-09-04

Publications (2)

Publication Number Publication Date
WO2003020985A1 true WO2003020985A1 (en) 2003-03-13
WO2003020985B1 WO2003020985B1 (en) 2003-05-01

Family

ID=25483747

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/027865 WO2003020985A1 (en) 2001-09-04 2002-09-03 Detection of genetic sequences using a bipartite probe

Country Status (4)

Country Link
US (4) US7011943B2 (en)
EP (1) EP1978110B1 (en)
TW (2) TWI313713B (en)
WO (1) WO2003020985A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10557851B2 (en) 2012-03-27 2020-02-11 Ventana Medical Systems, Inc. Signaling conjugates and methods of use

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1574801A (en) * 1999-10-26 2001-05-08 Genometrix Genomics Incorporated Process for requesting biological experiments and for the delivery of experimental information
US6432290B1 (en) 1999-11-26 2002-08-13 The Governors Of The University Of Alberta Apparatus and method for trapping bead based reagents within microfluidic analysis systems
CA2290731A1 (en) 1999-11-26 2001-05-26 D. Jed Harrison Apparatus and method for trapping bead based reagents within microfluidic analysis system
US20050272085A1 (en) * 2000-09-06 2005-12-08 Hodge Timothy A Methods for forensic and congenic screening
US7494817B2 (en) 2000-09-06 2009-02-24 Transnet Yx, Inc. Methods for genotype screening using magnetic particles
US20050239125A1 (en) * 2000-09-06 2005-10-27 Hodge Timothy A Methods for genotype screening
EP1978110B1 (en) * 2000-09-06 2010-05-26 Transnetyx, Inc. Computer-based method and system for screening genomic DNA
US20030087286A1 (en) * 2000-09-06 2003-05-08 Hodge Timothy A. Isolation of eukaryotic genomic DNA using magnetically responsive solid functionalized particles
US20030082605A1 (en) * 2000-09-06 2003-05-01 Hodge Timothy A. Genomic DNA detection method and system thereof
US20050266494A1 (en) * 2000-09-06 2005-12-01 Hodge Timothy A System and method for computer network ordering of biological testing
US20030207289A1 (en) * 2001-09-04 2003-11-06 Hodge Timothy A. Detection of genetic sequences using a bipartite probe
US20060014186A1 (en) * 2001-09-04 2006-01-19 Hodge Timothy A Methods for genotype screening of a strain disposed on an adsorbent carrier
US8155886B2 (en) * 2002-08-07 2012-04-10 Cerner Innovation, Inc. Automated clinical system to facilitate secondary review and authentication of clinical laboratory result values
US7648678B2 (en) 2002-12-20 2010-01-19 Dako Denmark A/S Method and system for pretreatment of tissue slides
US7445926B2 (en) 2002-12-30 2008-11-04 The Regents Of The University Of California Fluid control structures in microfluidic devices
US7799553B2 (en) 2004-06-01 2010-09-21 The Regents Of The University Of California Microfabricated integrated DNA analysis system
JP4476050B2 (en) * 2004-06-30 2010-06-09 株式会社ニデック Perimeter
EP1794581A2 (en) 2004-09-15 2007-06-13 Microchip Biotechnologies, Inc. Microfluidic devices
CH703675B1 (en) * 2005-11-16 2012-03-15 Suisse Electronique Microtech Process for producing J aggregates
JP5063616B2 (en) 2006-02-03 2012-10-31 インテジェニックス インコーポレイテッド Microfluidic device
US7766033B2 (en) 2006-03-22 2010-08-03 The Regents Of The University Of California Multiplexed latching valves for microfluidic devices and processors
US9328326B2 (en) * 2006-08-10 2016-05-03 Merck Patent Gmbh Method for isolating cells
US8841116B2 (en) 2006-10-25 2014-09-23 The Regents Of The University Of California Inline-injection microdevice and microfabricated integrated DNA analysis system using same
CN101715483A (en) 2007-02-05 2010-05-26 微芯片生物工艺学股份有限公司 microfluidic and nanofluidic devices, systems, and applications
JP4887174B2 (en) * 2007-02-19 2012-02-29 株式会社日立ハイテクノロジーズ Automatic analyzer
WO2009015296A1 (en) 2007-07-24 2009-01-29 The Regents Of The University Of California Microfabricated dropley generator
WO2009108260A2 (en) 2008-01-22 2009-09-03 Microchip Biotechnologies, Inc. Universal sample preparation system and use in an integrated analysis system
EP2250286A1 (en) 2008-02-15 2010-11-17 Life Technologies Corporation Methods and compositions for shearing of polymers by sonication
US8731956B2 (en) * 2008-03-21 2014-05-20 Signature Genomic Laboratories Web-based genetics analysis
US20100281401A1 (en) * 2008-11-10 2010-11-04 Signature Genomic Labs Interactive Genome Browser
US8672532B2 (en) 2008-12-31 2014-03-18 Integenx Inc. Microfluidic methods
US20100240049A1 (en) 2009-01-16 2010-09-23 Cepheid Methods of Detecting Cervical Cancer
EP2628803A3 (en) * 2009-02-25 2014-01-01 Cepheid Methods of detecting lung cancer
CN102459565A (en) 2009-06-02 2012-05-16 尹特根埃克斯有限公司 Fluidic devices with diaphragm valves
JP2012529268A (en) 2009-06-05 2012-11-22 インテジェンクス,インコーポレイテッド Use of universal sample preparation system and integrated analysis system
US8584703B2 (en) * 2009-12-01 2013-11-19 Integenx Inc. Device with diaphragm valve
US8512538B2 (en) 2010-05-28 2013-08-20 Integenx Inc. Capillary electrophoresis device
EP3100786A1 (en) 2010-07-22 2016-12-07 Gencell Biosystems Limited Composite liquid cells
US9121058B2 (en) 2010-08-20 2015-09-01 Integenx Inc. Linear valve arrays
US8763642B2 (en) 2010-08-20 2014-07-01 Integenx Inc. Microfluidic devices with mechanically-sealed diaphragm valves
CN103703142A (en) 2011-01-26 2014-04-02 西菲伊德公司 Methods of detecting lung cancer
US20150136604A1 (en) 2011-10-21 2015-05-21 Integenx Inc. Sample preparation, processing and analysis systems
US10865440B2 (en) 2011-10-21 2020-12-15 IntegenX, Inc. Sample preparation, processing and analysis systems
DE102012102918A1 (en) * 2012-04-03 2013-10-10 Eppendorf Ag Laboratory device system and laboratory device for treating fluids and solids, and method for operating a laboratory device
US9776182B2 (en) 2012-11-27 2017-10-03 Gencell Biosystems Ltd. Handling liquid samples
US20140272971A1 (en) * 2013-03-14 2014-09-18 Health Diagnostic Laboratory, Inc. Unheated extraction of genomic dna in an automated laboratory system
WO2015073999A1 (en) 2013-11-18 2015-05-21 Integenx Inc. Cartridges and instruments for sample analysis
EP3105326A4 (en) * 2014-02-10 2018-01-10 Gencell Biosystems Limited Composite liquid cell (clc) mediated nucleic acid library preparation device, and methods for using the same
GB2544198B (en) 2014-05-21 2021-01-13 Integenx Inc Fluidic cartridge with valve mechanism
CN107106983B (en) 2014-10-22 2021-04-16 尹特根埃克斯有限公司 Systems and methods for sample preparation, processing, and analysis
CA3005265A1 (en) * 2015-12-31 2017-07-06 Counsyl, Inc. Robotic system for sorting sample tubes
US11361847B1 (en) 2021-02-06 2022-06-14 Timothy A. Hodge System and method for rapidly reporting testing results
CN116024320A (en) * 2022-07-13 2023-04-28 上海翔琼生物技术有限公司 Fluorescent quantitative PCR method for detecting nucleic acid

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837865A (en) * 1993-10-15 1998-11-17 Trustees Of The University Of Pennsylvania Phosphorescent dendritic macromolecular compounds for imaging tissue oxygen
US6046038A (en) * 1996-06-04 2000-04-04 Poly Probe, Inc. Optimally labeled oligonucleotides
US6110687A (en) * 1996-10-29 2000-08-29 Polyprobe, Inc. Detection of antigens via oligonucleotide antibody conjugates
US6261779B1 (en) * 1998-11-10 2001-07-17 Bio-Pixels Ltd. Nanocrystals having polynucleotide strands and their use to form dendrimers in a signal amplification system

Family Cites Families (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4154795A (en) * 1976-07-23 1979-05-15 Dynatech Holdings Limited Microtest plates
US4695393A (en) 1983-05-12 1987-09-22 Advanced Magnetics Inc. Magnetic particles for use in separations
US4628037A (en) 1983-05-12 1986-12-09 Advanced Magnetics, Inc. Binding assays employing magnetic particles
US4698302A (en) 1983-05-12 1987-10-06 Advanced Magnetics, Inc. Enzymatic reactions using magnetic particles
US4672040A (en) 1983-05-12 1987-06-09 Advanced Magnetics, Inc. Magnetic particles for use in separations
US4554088A (en) 1983-05-12 1985-11-19 Advanced Magnetics Inc. Magnetic particles for use in separations
DE3474790D1 (en) 1983-07-30 1988-12-01 Johannes Bendig Film processing machine
US4563417A (en) * 1984-08-31 1986-01-07 Miles Laboratories, Inc. Nucleic acid hybridization assay employing antibodies to intercalation complexes
US5656493A (en) 1985-03-28 1997-08-12 The Perkin-Elmer Corporation System for automated performance of the polymerase chain reaction
US4920213A (en) * 1985-06-20 1990-04-24 Biotechnology Research Partners, Ltd. Method and compositions useful in preventing equine influenza
US5721098A (en) 1986-01-16 1998-02-24 The Regents Of The University Of California Comparative genomic hybridization
US5139744A (en) 1986-03-26 1992-08-18 Beckman Instruments, Inc. Automated laboratory work station having module identification means
US5175270A (en) * 1986-09-10 1992-12-29 Polyprobe, Inc. Reagents for detecting and assaying nucleic acid sequences
US6054266A (en) 1987-12-21 2000-04-25 Applied Biosystems, Inc. Nucleic acid detection with separation
US6054270A (en) 1988-05-03 2000-04-25 Oxford Gene Technology Limited Analying polynucleotide sequences
CA1339731C (en) 1988-10-12 1998-03-17 Charles T. Caskey Multiplex genomic dna amplification for deletion detection
US5196306A (en) 1989-03-29 1993-03-23 E. I. Du Pont De Nemours And Company Method for the detection or quantitation of an analyte using an analyte dependent enzyme activation system
US5182203A (en) 1989-03-29 1993-01-26 E. I. Du Pont De Nemours And Company Bifunctional compounds useful in catalyzed reporter deposition
US5413923A (en) * 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5355304A (en) 1990-01-30 1994-10-11 Demoranville Victoria E Clinical laboratory work-flow system which semi-automates validated immunoassay and electrophoresis protocols
GB9003253D0 (en) 1990-02-13 1990-04-11 Amersham Int Plc Precipitating polymers
IT1240870B (en) 1990-02-14 1993-12-17 Talent PROCEDURE FOR THE EXTRACTION AND PURIFICATION OF HUMAN GENOMIC DNA
US5219991A (en) * 1990-09-21 1993-06-15 The United States Of America As Represented By The Department Of Health And Human Services Macrophage stimulating protein
WO1992015694A1 (en) 1991-03-08 1992-09-17 The Salk Institute For Biological Studies Flp-mediated gene modification in mammalian cells, and compositions and cells useful therefor
US6055487A (en) * 1991-07-30 2000-04-25 Margery; Keith S. Interactive remote sample analysis system
US5366896A (en) 1991-07-30 1994-11-22 University Of Virginia Alumni Patents Foundation Robotically operated laboratory system
US6192320B1 (en) * 1991-07-30 2001-02-20 The University Of Virginia Patent Foundation Interactive remote sample analysis system
WO1993003150A1 (en) 1991-07-31 1993-02-18 Amoco Corporation Simultaneous shear and denaturation of nucleic acids
PT620849E (en) 1992-01-07 2003-11-28 Elan Pharm Inc TRANSGENIC ANIMAL MODELS FOR ALZHEIMER'S DISEASE
US5888723A (en) 1992-02-18 1999-03-30 Johnson & Johnson Clinical Diagnostics, Inc. Method for nucleic acid amplification and detection using adhered probes
WO1993018186A1 (en) 1992-03-04 1993-09-16 The Regents Of The University Of California Comparative genomic hybridization (cgh)
GB9212164D0 (en) 1992-06-09 1992-07-22 Medical Res Council Preparation of nucleic acids
US5859230A (en) * 1992-07-30 1999-01-12 Genelabs Technologies, Inc. Non-A/non-B/non-C/non-D/non-E hepatitis agents and molecular cloning thereof
DE4236708A1 (en) * 1992-10-30 1994-05-05 Bayer Ag Specific gene probes and methods for the diagnosis of Candida albicans
AU5546594A (en) 1992-11-06 1994-06-08 Abbott Laboratories Process control system for biological fluid testing
US5427910A (en) * 1992-12-09 1995-06-27 Compucyte Corporation Method of cytogenetic analysis
US5733753A (en) 1992-12-22 1998-03-31 Novo Nordisk A/S Amplification of genomic DNA by site specific integration of a selectable marker construct
US5527695A (en) 1993-01-29 1996-06-18 Purdue Research Foundation Controlled modification of eukaryotic genomes
JP3696238B2 (en) 1993-08-30 2005-09-14 プロメガ・コーポレイシヨン Nucleic acid purification composition and method
US6156501A (en) 1993-10-26 2000-12-05 Affymetrix, Inc. Arrays of modified nucleic acid probes and methods of use
GB9323305D0 (en) 1993-11-11 1994-01-05 Medinnova Sf Isoaltion of nucleic acid
US5863726A (en) * 1993-11-12 1999-01-26 Geron Corporation Telomerase activity assays
US5596089A (en) 1994-02-14 1997-01-21 Universite De Montreal Oligonucleotide probe and primers specific to bovine or porcine male genomic DNA
US5932780A (en) 1994-02-28 1999-08-03 Yissum Research Development Company Of Hebrew University Of Jerusalem Transgenic non-human animal assay system for anti-cholinesterase substances
US5962477A (en) * 1994-04-12 1999-10-05 Adolor Corporation Screening methods for cytokine inhibitors
US6037465A (en) 1994-06-14 2000-03-14 Invitek Gmbh Universal process for isolating and purifying nucleic acids from extremely small amounts of highly contaminated various starting materials
US5624899A (en) * 1994-07-20 1997-04-29 Genentech Inc. Method for using Htk ligand
US5658744A (en) * 1994-07-22 1997-08-19 The United States Of America As Represented By The Department Of Health And Human Services Methods of identifying patients having an altered immune status
US6800452B1 (en) 1994-08-08 2004-10-05 Science Applications International Corporation Automated methods for simultaneously performing a plurality of signal-based assays
US5705628A (en) 1994-09-20 1998-01-06 Whitehead Institute For Biomedical Research DNA purification and isolation using magnetic particles
AT401270B (en) 1994-09-26 1996-07-25 Immuno Ag METHOD FOR QUANTIFYING GENOMIC DNA
GB9425138D0 (en) * 1994-12-12 1995-02-08 Dynal As Isolation of nucleic acid
US5576197A (en) * 1995-04-07 1996-11-19 Molecular Bio-Products Polymerase chain reaction container and methods of using the same
DE19520398B4 (en) 1995-06-08 2009-04-16 Roche Diagnostics Gmbh Magnetic pigment
JP2965131B2 (en) * 1995-07-07 1999-10-18 東洋紡績株式会社 Magnetic carrier for nucleic acid binding and nucleic acid isolation method using the same
US5851599A (en) * 1995-09-28 1998-12-22 Sumitomo Electric Industries Co., Ltd. Battery electrode substrate and process for producing the same
US6114150A (en) 1995-11-29 2000-09-05 Yale University Amplification of nucleic acids
US5668548A (en) * 1995-12-28 1997-09-16 Philips Electronics North America Corp. High performance variable length decoder with enhanced throughput due to tagging of the input bit stream and parallel processing of contiguous code words
JP3735937B2 (en) * 1996-04-16 2006-01-18 宇部興産株式会社 Terminal cap and cylindrical non-aqueous secondary battery using them
US5804382A (en) 1996-05-10 1998-09-08 Beth Israel Deaconess Medical Center, Inc. Methods for identifying differentially expressed genes and differences between genomic nucleic acid sequences
EP0912761A4 (en) * 1996-05-29 2004-06-09 Cornell Res Foundation Inc Detection of nucleic acid sequence differences using coupled ligase detection and polymerase chain reactions
US6117635A (en) 1996-07-16 2000-09-12 Intergen Company Nucleic acid amplification oligonucleotides with molecular energy transfer labels and methods based thereon
US7098320B1 (en) * 1996-07-29 2006-08-29 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US5942402A (en) * 1996-08-02 1999-08-24 Smithkline Beecham Corporation Method of detecting and treating cancer
US5731095A (en) 1996-10-23 1998-03-24 Oxazogen, Inc. Dendritic polymer coatings
US5968731A (en) 1996-12-10 1999-10-19 The Regents Of The University Of California Apparatus for automated testing of biological specimens
US5841975A (en) 1996-12-10 1998-11-24 The Regents Of The University Of California Method and apparatus for globally-accessible automated testing
US6060240A (en) 1996-12-13 2000-05-09 Arcaris, Inc. Methods for measuring relative amounts of nucleic acids in a complex mixture and retrieval of specific sequences therefrom
US5837466A (en) 1996-12-16 1998-11-17 Vysis, Inc. Devices and methods for detecting nucleic acid analytes in samples
DE19653439A1 (en) 1996-12-20 1998-07-02 Svante Dr Paeaebo Methods for the direct, exponential amplification and sequencing of DNA molecules and their application
US6027945A (en) 1997-01-21 2000-02-22 Promega Corporation Methods of isolating biological target materials using silica magnetic particles
US20050287583A1 (en) 1997-01-21 2005-12-29 Promega Corporation Methods and kits for isolating biological target materials using silica magnetic particles
CA2281205A1 (en) * 1997-02-12 1998-08-13 Eugene Y. Chan Methods and products for analyzing polymers
HUP0003152A3 (en) * 1997-02-28 2002-09-30 Burstein Lab Inc Irvine Laboratory in a disk
US20020012934A1 (en) 1997-03-07 2002-01-31 Meghen Ciaran N. Business method for identification of a meat product by genotyping
CA2283432A1 (en) 1997-03-07 1998-09-11 Parlanca Limited A method and system of identification of a meat product by genotyping
US5842573A (en) * 1997-03-11 1998-12-01 Halvorsen; Yuan-Di C. Method of transporting cells and kit useful therefor
IL120672A (en) 1997-04-15 2000-06-29 Nush Marketing Man And Consult System for transaction over communication network
DE69841139D1 (en) 1997-07-14 2009-10-22 Univ Liege MUTATIONS IN MYOSTATINGEN INCREASE MUSCLE MASS IN MAMMALS
JP4221145B2 (en) * 1997-07-29 2009-02-12 ポリプローブ,インコーポレイテッド Dendritic nucleic acid for maximum self-assembly
US6465178B2 (en) * 1997-09-30 2002-10-15 Surmodics, Inc. Target molecule attachment to surfaces
EP1071691B1 (en) 1998-02-04 2005-09-28 MERCK PATENT GmbH Method for isolating and purifying nucleic acids
US6043039A (en) 1998-02-17 2000-03-28 Applied Spectral Imaging Method of and composite for in situ fluorescent hybridization
US6187537B1 (en) 1998-04-27 2001-02-13 Donald E. Zinn, Jr. Process and apparatus for forming a dry DNA transfer film, a transfer film product formed thereby and an analyzing process using the same
US6287765B1 (en) * 1998-05-20 2001-09-11 Molecular Machines, Inc. Methods for detecting and identifying single molecules
US6132685A (en) * 1998-08-10 2000-10-17 Caliper Technologies Corporation High throughput microfluidic systems and methods
US6203989B1 (en) * 1998-09-30 2001-03-20 Affymetrix, Inc. Methods and compositions for amplifying detectable signals in specific binding assays
US6480791B1 (en) 1998-10-28 2002-11-12 Michael P. Strathmann Parallel methods for genomic analysis
US5973138A (en) 1998-10-30 1999-10-26 Becton Dickinson And Company Method for purification and manipulation of nucleic acids using paramagnetic particles
DE19851156C1 (en) 1998-11-06 2000-04-27 Merck Patent Gmbh Isolation of plasmid DNA from a microbial culture comprises acidification and using particles to separate microbial cells from the culture
DE19856064C2 (en) * 1998-12-04 2000-11-30 Invitek Gmbh Universal method for the isolation of DNA from any starting material
US20030215821A1 (en) 1999-04-20 2003-11-20 Kevin Gunderson Detection of nucleic acid reactions on bead arrays
CA2270106C (en) 1999-04-23 2006-03-14 Yousef Haj-Ahmad Nucleic acid purification and process
US6270970B1 (en) 1999-05-14 2001-08-07 Promega Corporation Mixed-bed solid phase and its use in the isolation of nucleic acids
US6180351B1 (en) * 1999-07-22 2001-01-30 Agilent Technologies Inc. Chemical array fabrication with identifier
US6362832B1 (en) * 1999-09-01 2002-03-26 Packard Bioscience Company Method and system for overlaying at least three microarray images to obtain a multicolor composite image
US6730023B1 (en) * 1999-10-15 2004-05-04 Hemopet Animal genetic and health profile database management
DE19955729A1 (en) * 1999-11-15 2001-05-23 Hospitalia Dienstleistungs & B Communication system for the interaction of medical laboratories and medical treatment facilities
US6274321B1 (en) * 1999-12-03 2001-08-14 The Regents Of The University Of California High throughput functional screening of cDNAs
US20010032060A1 (en) * 1999-12-13 2001-10-18 Igor Markidan Tracking of clinical study samples, information and results
US20030097222A1 (en) * 2000-01-25 2003-05-22 Craford David M. Method, system, and computer software for providing a genomic web portal
US6556923B2 (en) * 2000-01-26 2003-04-29 Caliper Technologies Corp. Software for high throughput microfluidic systems
CA2377005A1 (en) * 2000-04-18 2001-10-25 Combimatrix Corporation Automated system and process for custom-designed biological array design and analysis
US20030082605A1 (en) 2000-09-06 2003-05-01 Hodge Timothy A. Genomic DNA detection method and system thereof
US7494817B2 (en) * 2000-09-06 2009-02-24 Transnet Yx, Inc. Methods for genotype screening using magnetic particles
EP1978110B1 (en) * 2000-09-06 2010-05-26 Transnetyx, Inc. Computer-based method and system for screening genomic DNA
US20050272085A1 (en) * 2000-09-06 2005-12-08 Hodge Timothy A Methods for forensic and congenic screening
US20050239125A1 (en) * 2000-09-06 2005-10-27 Hodge Timothy A Methods for genotype screening
US20050266494A1 (en) * 2000-09-06 2005-12-01 Hodge Timothy A System and method for computer network ordering of biological testing
US20030087286A1 (en) 2000-09-06 2003-05-08 Hodge Timothy A. Isolation of eukaryotic genomic DNA using magnetically responsive solid functionalized particles
US20030207289A1 (en) 2001-09-04 2003-11-06 Hodge Timothy A. Detection of genetic sequences using a bipartite probe
AU2001286262A1 (en) 2000-09-18 2002-04-02 Center For Advanced Science And Technology Incubation, Ltd. (Casti) Micro well array and method of sealing liquid using the micro well array
IL138988A (en) * 2000-10-12 2005-09-25 Yissum Res Dev Co Dendritically amplified detection method
US20040018491A1 (en) * 2000-10-26 2004-01-29 Kevin Gunderson Detection of nucleic acid reactions on bead arrays
US7045367B2 (en) * 2001-03-23 2006-05-16 Michigan Molecular Institute Nano-scaled dendrimer-based colorimetric biosensors
US20060014186A1 (en) * 2001-09-04 2006-01-19 Hodge Timothy A Methods for genotype screening of a strain disposed on an adsorbent carrier
US20030087295A1 (en) * 2001-10-31 2003-05-08 Millennium Pharmaceuticals, Inc. Methods and compositions for the treatment and diagnosis of pain disorders using 9805
DE60235491D1 (en) * 2001-11-28 2010-04-08 Bio Rad Laboratories PARALLEL SCORING OF POLYMORPHISMS WITH AMPLIFICATION AND ERROR CORRECTION
US20040023248A1 (en) * 2001-12-07 2004-02-05 Whitehead Institiute For Biomedical Research Methods and reagents for improving nucleic acid detection
DE60229890D1 (en) * 2002-09-30 2008-12-24 Hoffmann La Roche OLIGONUCLEOTIDES FOR GENOTYPIZING THE THYMIDYLATE SYNTHASE GENE
US7354706B2 (en) * 2003-09-09 2008-04-08 The Regents Of The University Of Colorado, A Body Corporate Use of photopolymerization for amplification and detection of a molecular recognition event
JP2007512811A (en) * 2003-11-10 2007-05-24 インベスチゲン, インコーポレイテッド Methods for preparing nucleic acids for detection

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837865A (en) * 1993-10-15 1998-11-17 Trustees Of The University Of Pennsylvania Phosphorescent dendritic macromolecular compounds for imaging tissue oxygen
US6046038A (en) * 1996-06-04 2000-04-04 Poly Probe, Inc. Optimally labeled oligonucleotides
US6110687A (en) * 1996-10-29 2000-08-29 Polyprobe, Inc. Detection of antigens via oligonucleotide antibody conjugates
US6261779B1 (en) * 1998-11-10 2001-07-17 Bio-Pixels Ltd. Nanocrystals having polynucleotide strands and their use to form dendrimers in a signal amplification system

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10557851B2 (en) 2012-03-27 2020-02-11 Ventana Medical Systems, Inc. Signaling conjugates and methods of use
US11906523B2 (en) 2012-03-27 2024-02-20 Ventana Medical Systems, Inc. Signaling conjugates and methods of use

Also Published As

Publication number Publication date
TWI322187B (en) 2010-03-21
TW200745346A (en) 2007-12-16
US20020177137A1 (en) 2002-11-28
US20030165922A1 (en) 2003-09-04
TWI313713B (en) 2009-08-21
US20050170423A1 (en) 2005-08-04
EP1978110A1 (en) 2008-10-08
US7011943B2 (en) 2006-03-14
US6977178B2 (en) 2005-12-20
US7282361B2 (en) 2007-10-16
WO2003020985B1 (en) 2003-05-01
EP1978110B1 (en) 2010-05-26
US20050221370A1 (en) 2005-10-06

Similar Documents

Publication Publication Date Title
WO2003020985A1 (en) Detection of genetic sequences using a bipartite probe
JP6959378B2 (en) Enzyme-free and amplification-free sequencing
US6579680B2 (en) Method for label-free detection of hybridized DNA targets
US6821724B1 (en) Methods of genetic analysis using nucleic acid arrays
JP4499987B2 (en) Solid support assay systems and methods using non-standard bases
JP2018042577A (en) Chimeric primers with hairpin conformation and use methods thereof
US20040009487A1 (en) Methods for blocking nonspecific hybridizations of nucleic acid sequences
US6261846B1 (en) Gene amplifying method
JP2012509078A (en) Real-time multiplex PCR detection on solid surface using double-stranded nucleic acid specific dye
JP2004506179A (en) Methods for detecting and analyzing nucleic acid sequences
EP1612282B1 (en) Probe set and substrate for detecting nucleic acid
JP6182300B2 (en) Target nucleic acid detection method
JP2021531778A (en) Nucleic acid detection method
Lane et al. Amplicon secondary structure prevents target hybridization to oligonucleotide microarrays
EP1169474A1 (en) Olignucleotide array and methods of use
Germini et al. Detection of genetically modified soybean using peptide nucleic acids (PNAs) and microarray technology
US20030207289A1 (en) Detection of genetic sequences using a bipartite probe
Romkes et al. Genotyping technologies: application to biotransformation enzyme genetic polymorphism screening
JP2003530893A (en) Detection of nucleotide sequence variation by proofreading activity of polymerase
US20040009514A1 (en) Assembly for label-free detection of hybridized nucleic targets
US20240002913A1 (en) Systems and methods for multiplexed analyte detection using antibody-oligonucleotide conjugates
US20050003366A1 (en) Method for reusing standard blots and microarrays utilizing DNA dendrimer technology
JP5681217B2 (en) Nucleic acid detection method through promotion of formation of branched DNA complex
US20150111774A1 (en) Method for Detecting Target Nucleic Acid
US20020094538A1 (en) Methods for detecting and assaying nucleic acid sequences using temperature cycling

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

B Later publication of amended claims

Free format text: 20030304

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP